Identification

Name
Prednisone
Accession Number
DB00635  (APRD00340)
Type
Small Molecule
Groups
Approved, Vet approved
Description

A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver. [PubChem]

Structure
Thumb
Synonyms
  • 1,2-Dehydrocortisone
  • 1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
  • 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
  • Dehydrocortisone
  • Prednisona
  • Prednisonum
External IDs
NSC-10023
Product Ingredients
IngredientUNIICASInChI Key
Prednisone acetateOU93QEL83U125-10-0MOVRKLZUVNCBIP-RFZYENFJSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Prednisone Tab 1mg USPTablet1 mgOralApotex Corporation1984-12-31Not applicableCanada
Apo Prednisone Tab 50mgTablet50 mgOralApotex Corporation1982-12-31Not applicableCanada
Apo Prednisone Tab 5mgTablet5 mgOralApotex Corporation1982-12-31Not applicableCanada
Deltasone 50mgTablet50 mgOralPharmacia & Upjohn Inc1972-12-312000-08-02Canada
Deltasone 5mgTablet5 mgOralPharmacia & Upjohn Inc1972-12-312000-08-02Canada
Jaa Prednisone Tab 1mg USPTablet1.0 mgOralJaapharm Canada Inc.1993-05-15Not applicableCanada
Jaa Prednisone Tab 50mg USPTablet50 mgOralJaapharm Canada Inc.1993-12-31Not applicableCanada
Jaa Prednisone Tab 5mg USPTablet5 mgOralJaapharm Canada Inc.1993-12-31Not applicableCanada
Prednisone 50 Tab 50mgTablet50 mgOralPro Doc Limitee1994-12-312016-07-18Canada
Prednisone Tab 5mgTablet5 mgOralEverest Pharmaceuticals Ltd.1980-12-311999-07-14Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-prednisone Tab 5mgTablet5 mgOralAltimed Pharma Inc.1984-12-311998-08-10Canada
DeltasoneTablet20 mg/20mgOralOculus Innovative Scicences2009-08-03Not applicableUs
Nu-prednisoneTablet5 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-prednisoneTablet1 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-prednisoneTablet50 mgOralNu Pharm IncNot applicableNot applicableCanada
Perrigo PrednisoneTablet20 mg/1OralPerrigo International2006-10-112017-10-26Us
Perrigo PrednisoneTablet5 mg/1OralPerrigo International2006-05-192017-10-26Us
Perrigo PrednisoneTablet10 mg/1OralPerrigo International2006-05-192017-10-26Us
PrednisoneTablet20 mg/1OralPreferreed Pharmaceuticals Inc.2015-03-26Not applicableUs
PredniSONETablet20 mg/1OralC.O. Truxton, Inc.2003-02-13Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Metreton TabPrednisone (2.5 mg) + Ascorbic acid (75 mg) + Chlorpheniramine maleate (2 mg)TabletOralSchering Plough1956-12-312007-08-03Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Contrast Allergy PreMed PackPrednisone + DiphenhydramineKitShertech Laboratories, Llc2016-09-13Not applicableUs
International/Other Brands
Delta-Cortef (Upjohn) / Meticorten / Orasone
Categories
UNII
VB0R961HZT
CAS number
53-03-2
Weight
Average: 358.4281
Monoisotopic: 358.178023942
Chemical Formula
C21H26O5
InChI Key
XOFYZVNMUHMLCC-ZPOLXVRWSA-N
InChI
InChI=1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1
IUPAC Name
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-diene-5,17-dione
SMILES
[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C

Pharmacology

Indication

For the treatment of drug-induced allergic reactions, perennial or seasonal allergic rhinitis, serum sickness, giant cell arteritis acute rheumatic or nonrheumatic carditis, systemic dermatomyositis, systemic lupus erythematosus, atopic dermatitis, contact dermatitis, exfoliative dermatitis, bullous dermatitis herpetiformis, severe seborrheic dermatitis, severe (Stevens-Johnson syndrome) erythema multiforme, mycosis fungoides, pemphigus, severe psoriasis, acute adrenocortical insufficiency, Addison's disease, secondary adrenocortical insufficiency, congenital adrenal hyperplasia, hypercalcemia associated with neoplasms, nonsuppurative thyroiditis, ulceratice colitis, Crohn's disease, acquired hemolytic anemia, congenital hypoplastic anemia, erythroblastopenia, adult secondary thrombocytopenia, adult idiopathic thrombocytopenia purpura, acute or subacute bursitis, epicondylitis, acute nonspecific tenosynovitis, acute or chronic lymphocytic leukemia, Hodgkin's or non-Hodgkin's lynphomas, Waldenstrom's macroglobulinemia, primary brain tumors (adjunct), nephrotic syndrome, tuberculous meningitis, multiple sclerosis, myasthenia gravis. cerebral edema, chorioretinitis, diffuse posterior choroiditis, aleergic conjunctivitis, Herpes zoster ophthalmicus, anterior segment inflammation, iridocyclitis, iritis, keratitis, optoc neuritis, sympathetic ophthalmia, corneal marginal allergic ulcers, symptomatic sarcoidosis, Loeffler's syndrome not manageable by other means, berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy and aspiration pneumonitis.

Associated Conditions
Pharmacodynamics

Prednisone, the most commonly-prescribed corticosteroid, is used to treat allograft rejection, asthma, systemic lupus erythematosus, and many other inflammatory states. Prednisone has some mineralocorticoid activity and thus may affect ion exchange in the kidney.

Mechanism of action

Prednisone is a glucocorticoid receptor agonist. It is first metabolized in the liver to its active form, prednisolone. Prednisolone crosses cell membranes and binds with high affinity to specific cytoplasmic receptors. The result includes inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, suppression of humoral immune responses, and reduction in edema or scar tissue. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisone can stimulate secretion of various components of gastric juice. Suppression of the production of corticotropin may lead to suppression of endogenous corticosteroids. Prednisone has slight mineralocorticoid activity, whereby entry of sodium into cells and loss of intracellular potassium is stimulated. This is particularly evident in the kidney, where rapid ion exchange leads to sodium retention and hypertension.

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Human
UCorticosteroid 11-beta-dehydrogenase isozyme 1
ligand
Human
Absorption

Readily absorbed from the gastrointestinal tract. Rayos, the delayed-release formulation, has a 4-hour release time. To compare, the delayed-release formulation has a Tmax of 6.0 - 6.5 hours in healthy male subjects, whereas the immediate-release formulation has a Tmax of 2.0 hours. The rate of absorption, Cmax, and exposure is comparable between formulations.

Volume of distribution
Not Available
Protein binding

Extensively bound to plasma proteins.

Metabolism

Prednisone is completely converted to the active metabolite prednisolone by 11β-hydroxysteroid dehydrogenases. It is then further metabolized mainly in the liver. The exposure of prednisolone is 4-6 fold higher than that of prednisone.

Route of elimination

Excreted in the urine as sulfate and glucuronide conjugates.

Half life

Half life of both the immediate- and delayed- release formulation is 2 to 3 hours.

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Prednisone Action PathwayDrug action
Prednisone Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINEThe therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Prednisone.Experimental
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Prednisone.Investigational
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Prednisone is combined with 1,10-Phenanthroline.Experimental
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Prednisone.Investigational
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Prednisone.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Prednisone.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Prednisone.Approved, Experimental, Investigational
AcetaminophenThe serum concentration of Prednisone can be increased when it is combined with Acetaminophen.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Prednisone.Approved, Investigational, Withdrawn
Acetyl sulfisoxazoleThe metabolism of Prednisone can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Prednisone.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Prednisone.Experimental
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Prednisone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Prednisone.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Prednisone.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Prednisone.Experimental, Investigational
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Prednisone.Approved, Withdrawn
AldesleukinPrednisone may decrease the antineoplastic activities of Aldesleukin.Approved
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Prednisone.Investigational
AlmasilateThe bioavailability of Prednisone can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Prednisone.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Prednisone.Approved
AloglutamolThe bioavailability of Prednisone can be decreased when combined with Aloglutamol.Approved
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Prednisone.Experimental
AluminiumThe bioavailability of Prednisone can be decreased when combined with Aluminium.Approved, Investigational
Aluminium acetoacetateThe bioavailability of Prednisone can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Prednisone can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Prednisone can be decreased when combined with Aluminum hydroxide.Approved, Investigational
AmbenoniumThe risk or severity of adverse effects can be increased when Prednisone is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Prednisone.Approved
AmiodaroneThe serum concentration of Prednisone can be increased when it is combined with Amiodarone.Approved, Investigational
AmlodipineThe serum concentration of Prednisone can be increased when it is combined with Amlodipine.Approved
Amphotericin BPrednisone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Prednisone.Approved, Investigational, Withdrawn
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Prednisone.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Prednisone.Investigational
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Prednisone is combined with Anthrax immune globulin human.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Prednisone.Approved, Investigational
AntrafenineThe risk or severity of adverse effects can be increased when Prednisone is combined with Antrafenine.Approved
ApalutamideThe serum concentration of Prednisone can be decreased when it is combined with Apalutamide.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Prednisone.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Prednisone.Approved, Investigational
AprepitantThe serum concentration of Prednisone can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Prednisone.Approved, Investigational
AsunaprevirThe serum concentration of Asunaprevir can be decreased when it is combined with Prednisone.Approved, Investigational, Withdrawn
AtazanavirThe serum concentration of Prednisone can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Prednisone can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Prednisone is combined with Atorvastatin.Approved
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Prednisone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Prednisone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Prednisone.Approved
AzosemidePrednisone may increase the hypokalemic activities of Azosemide.Investigational
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when Prednisone is combined with Bacillus calmette-guerin substrain connaught live antigen.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of adverse effects can be increased when Prednisone is combined with Bacillus calmette-guerin substrain tice live antigen.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Prednisone.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Prednisone.Approved, Investigational
BazedoxifeneThe serum concentration of Prednisone can be increased when it is combined with Bazedoxifene.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Prednisone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Prednisone is combined with Beclomethasone dipropionate.Approved, Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Prednisone.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Prednisone.Experimental
BendroflumethiazidePrednisone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Prednisone.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Prednisone.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Prednisone.Approved, Investigational
BenzthiazidePrednisone may increase the hypokalemic activities of Benzthiazide.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Prednisone.Approved
Benzyl alcoholThe serum concentration of Prednisone can be increased when it is combined with Benzyl alcohol.Approved
BepridilThe serum concentration of Prednisone can be increased when it is combined with Bepridil.Approved, Withdrawn
BevacizumabBevacizumab may increase the cardiotoxic activities of Prednisone.Approved, Investigational
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Prednisone.Experimental
Bismuth subcitrate potassiumThe bioavailability of Prednisone can be decreased when combined with Bismuth Subcitrate.Approved, Investigational
Bismuth subnitrateThe bioavailability of Prednisone can be decreased when combined with Bismuth subnitrate.Approved
BoceprevirThe serum concentration of Prednisone can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Prednisone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Prednisone can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Prednisone.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Prednisone.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Prednisone.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Prednisone.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Prednisone.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Prednisone is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Prednisone.Approved, Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Prednisone.Investigational, Withdrawn
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Prednisone.Experimental
BumetanidePrednisone may increase the hypokalemic activities of Bumetanide.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Prednisone.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Prednisone.Approved
CaffeineThe serum concentration of Prednisone can be increased when it is combined with Caffeine.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Prednisone.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Prednisone can be decreased when combined with Calcium Carbonate.Approved, Investigational
Calcium silicateThe bioavailability of Prednisone can be decreased when combined with Calcium silicate.Experimental
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Prednisone.Approved
Capromab pendetidePrednisone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CapsaicinThe risk or severity of adverse effects can be increased when Prednisone is combined with Capsaicin.Approved
CarbamazepineThe serum concentration of Prednisone can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Prednisone.Experimental, Investigational
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Prednisone.Experimental
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Prednisone.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of Prednisone can be increased when it is combined with Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Prednisone.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Prednisone.Approved, Investigational
CeritinibThe serum concentration of Prednisone can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Prednisone.Approved, Withdrawn
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Prednisone.Approved, Investigational, Vet Approved
ChlorothiazidePrednisone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Prednisone can be increased when it is combined with Chlorotrianisene.Investigational, Withdrawn
ChlorphenesinThe risk or severity of adverse effects can be increased when Prednisone is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Prednisone.Approved, Investigational
ChlorthalidonePrednisone may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Prednisone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Prednisone.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Prednisone.Experimental
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Prednisone.Approved, Investigational
CimicoxibThe risk or severity of adverse effects can be increased when Prednisone is combined with Cimicoxib.Investigational
CinoxacinThe risk or severity of adverse effects can be increased when Prednisone is combined with Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Prednisone.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Prednisone is combined with Cisplatin.Approved
ClarithromycinThe serum concentration of Prednisone can be increased when it is combined with Clarithromycin.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Prednisone is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Prednisone.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Prednisone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ClotrimazoleThe serum concentration of Prednisone can be increased when it is combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Prednisone can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Prednisone.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Prednisone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Prednisone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Prednisone.Approved, Investigational
Conjugated estrogensThe serum concentration of Prednisone can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Prednisone.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Prednisone is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Prednisone is combined with Coumaphos.Vet Approved
CrizotinibThe metabolism of Prednisone can be decreased when combined with Crizotinib.Approved
CurcuminThe serum concentration of Prednisone can be increased when it is combined with Curcumin.Approved, Investigational
CyclopenthiazidePrednisone may increase the hypokalemic activities of Cyclopenthiazide.Experimental
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Prednisone.Approved, Investigational
CyclosporineThe serum concentration of the active metabolites of Prednisone can be increased when Prednisone is used in combination with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Prednisone.Experimental
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Prednisone.Approved
DabrafenibThe serum concentration of Prednisone can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaidzeinThe serum concentration of Prednisone can be increased when it is combined with Daidzein.Experimental
DanazolPrednisone may increase the fluid retaining activities of Danazol.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Prednisone.Approved
DarunavirThe serum concentration of Prednisone can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Prednisone can be increased when it is combined with Dasatinib.Approved, Investigational
DecamethoniumThe risk or severity of adverse effects can be increased when Prednisone is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Prednisone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Prednisone can be decreased when combined with Delavirdine.Approved
DemecariumThe risk or severity of adverse effects can be increased when Prednisone is combined with Demecarium.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Prednisone.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Prednisone.Investigational
DersalazineThe risk or severity of adverse effects can be increased when Dersalazine is combined with Prednisone.Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Prednisone.Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Prednisone is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Prednisone is combined with Dexketoprofen.Approved, Investigational
DexniguldipineThe serum concentration of Prednisone can be increased when it is combined with Dexniguldipine.Experimental
DexverapamilThe serum concentration of Prednisone can be increased when it is combined with Dexverapamil.Experimental
DichlorvosThe risk or severity of adverse effects can be increased when Prednisone is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of gastrointestinal irritation can be increased when Prednisone is combined with Diclofenac.Approved, Vet Approved
DienestrolThe serum concentration of Prednisone can be increased when it is combined with Dienestrol.Approved, Investigational
DiethylstilbestrolThe serum concentration of Prednisone can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Prednisone.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Prednisone.Approved, Investigational
DigitoxinDigitoxin may decrease the cardiotoxic activities of Prednisone.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Prednisone.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Prednisone.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Prednisone.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Prednisone.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Prednisone.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Prednisone.Approved, Investigational
DiltiazemThe serum concentration of Prednisone can be increased when it is combined with Diltiazem.Approved, Investigational
DipivefrinThe risk or severity of adverse effects can be increased when Prednisone is combined with Dipivefrin.Approved
DistigmineThe risk or severity of adverse effects can be increased when Prednisone is combined with Distigmine.Experimental
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Prednisone.Approved, Investigational
DonepezilThe risk or severity of adverse effects can be increased when Prednisone is combined with Donepezil.Approved
DoxazosinThe serum concentration of Prednisone can be increased when it is combined with Doxazosin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Prednisone.Approved, Investigational
DoxycyclineThe metabolism of Prednisone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Prednisone can be decreased when combined with Dronedarone.Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Prednisone.Withdrawn
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Prednisone.Approved, Investigational
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Prednisone.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Prednisone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Prednisone is combined with Echothiophate.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Prednisone.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Prednisone is combined with Edrophonium.Approved
EmopamilThe serum concentration of Prednisone can be increased when it is combined with Emopamil.Experimental
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Prednisone.Approved
EnglitazoneThe therapeutic efficacy of Englitazone can be decreased when used in combination with Prednisone.Experimental
EnoxacinThe risk or severity of adverse effects can be increased when Prednisone is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Prednisone can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Prednisone can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Prednisone.Approved
EpitizidePrednisone may increase the hypokalemic activities of Epitizide.Experimental
EquolThe serum concentration of Prednisone can be increased when it is combined with Equol.Investigational
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Prednisone.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Prednisone.Approved
ErythromycinThe metabolism of Prednisone can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Prednisone.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Prednisone can be increased when it is combined with Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Prednisone can be increased when it is combined with Estradiol cypionate.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Prednisone can be increased when it is combined with Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Prednisone can be increased when it is combined with Estrogens, esterified.Approved
EstroneThe serum concentration of Prednisone can be increased when it is combined with Estrone.Approved
Etacrynic acidPrednisone may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Prednisone.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Prednisone.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Prednisone.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Prednisone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Prednisone.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Prednisone.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Prednisone.Investigational, Nutraceutical
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Prednisone.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Prednisone.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Prednisone.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Prednisone.Experimental
FelodipineThe serum concentration of Prednisone can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Prednisone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Prednisone.Approved
FentanylThe serum concentration of Prednisone can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe risk or severity of adverse effects can be increased when Prednisone is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Prednisone.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Prednisone.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Prednisone.Experimental
FingolimodPrednisone may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinThe risk or severity of adverse effects can be increased when Prednisone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Prednisone.Approved, Withdrawn
FluconazoleThe serum concentration of Prednisone can be increased when it is combined with Fluconazole.Approved, Investigational
FlumequineThe risk or severity of adverse effects can be increased when Prednisone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Prednisone.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Prednisone.Experimental
FluoxetineThe serum concentration of Prednisone can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluoxymesteronePrednisone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Prednisone.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Prednisone is combined with Fluticasone propionate.Approved
FluvoxamineThe serum concentration of Prednisone can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Prednisone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Prednisone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Prednisone can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FurosemideThe risk or severity of hypokalemia can be increased when Prednisone is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Prednisone can be increased when it is combined with Fusidic Acid.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Prednisone is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Prednisone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Prednisone is combined with Gallamine Triethiodide.Approved
GallopamilThe serum concentration of Prednisone can be increased when it is combined with Gallopamil.Investigational
GarenoxacinThe risk or severity of adverse effects can be increased when Prednisone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Prednisone is combined with Gatifloxacin.Approved, Investigational
GemcitabineThe risk or severity of adverse effects can be increased when Gemcitabine is combined with Prednisone.Approved
GemifloxacinThe risk or severity of adverse effects can be increased when Prednisone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Prednisone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Prednisone is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Prednisone is combined with Ginkgo biloba.Approved, Investigational, Nutraceutical
GinsengThe risk or severity of adverse effects can be increased when Prednisone is combined with Ginseng.Approved, Investigational, Nutraceutical
GitoformateGitoformate may decrease the cardiotoxic activities of Prednisone.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Prednisone.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Prednisone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Prednisone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Prednisone.Approved, Investigational
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Prednisone.Approved, Investigational
GLPG-0492Prednisone may increase the fluid retaining activities of GLPG-0492.Investigational
GlyburideThe serum concentration of Prednisone can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Prednisone can be increased when it is combined with Glycerin.Approved, Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Prednisone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Prednisone is combined with Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Prednisone.Experimental
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Prednisone.Investigational
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Prednisone.Experimental
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Prednisone is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Prednisone is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HexestrolThe serum concentration of Prednisone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Prednisone.Investigational
Human rabies virus immune globulinThe risk or severity of adverse effects can be increased when Prednisone is combined with Human rabies virus immune globulin.Approved
Huperzine AThe risk or severity of adverse effects can be increased when Prednisone is combined with Huperzine A.Approved, Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Prednisone.Approved, Investigational
HydrochlorothiazidePrednisone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Prednisone.Approved, Illicit
HydrocortisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Hydrocortisone.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of adverse effects can be increased when Prednisone is combined with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of adverse effects can be increased when Prednisone is combined with Hydrocortisone butyrate.Approved, Vet Approved
HydroflumethiazidePrednisone may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of Prednisone can be decreased when combined with Hydrotalcite.Approved, Experimental, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Prednisone.Approved
IbuprofenThe serum concentration of Prednisone can be increased when it is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Prednisone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Prednisone.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Prednisone is combined with Icosapent.Approved, Nutraceutical
IdelalisibThe serum concentration of Prednisone can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Prednisone can be decreased when combined with Imatinib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Prednisone.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Prednisone.Approved
IndapamidePrednisone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Prednisone can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Prednisone.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Prednisone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Prednisone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Prednisone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Prednisone is combined with INGN 225.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Prednisone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Prednisone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Prednisone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Prednisone.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Prednisone.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Prednisone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Prednisone.Approved
IpidacrineThe risk or severity of adverse effects can be increased when Prednisone is combined with Ipidacrine.Experimental
IrinotecanThe risk or severity of adverse effects can be increased when Prednisone is combined with Irinotecan.Approved, Investigational
IsavuconazoleThe serum concentration of Prednisone can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Prednisone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Prednisone is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Prednisone.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Prednisone.Withdrawn
IsradipineThe serum concentration of Prednisone can be increased when it is combined with Isradipine.Approved, Investigational
ItraconazoleThe serum concentration of Prednisone can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Prednisone can be increased when it is combined with Ivacaftor.Approved
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Prednisone is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated).Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Prednisone.Experimental
KetoconazoleThe serum concentration of Prednisone can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Prednisone.Approved, Vet Approved
KetorolacThe risk or severity of gastrointestinal irritation can be increased when Prednisone is combined with Ketorolac.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Prednisone.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Prednisone.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Prednisone.Experimental
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Prednisone.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Prednisone is combined with Leflunomide.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Prednisone.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Prednisone is combined with Levofloxacin.Approved, Investigational
LevonorgestrelThe serum concentration of Prednisone can be increased when it is combined with Levonorgestrel.Approved, Investigational
LidocaineThe serum concentration of Prednisone can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Prednisone.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Prednisone.Approved
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Prednisone.Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Prednisone.Approved, Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Prednisone is combined with Lomefloxacin.Approved, Investigational
LomerizineThe serum concentration of Prednisone can be increased when it is combined with Lomerizine.Experimental
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Prednisone.Experimental
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Prednisone.Approved
LopinavirThe serum concentration of Prednisone can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Prednisone can be increased when it is combined with Loratadine.Approved, Investigational
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Prednisone.Approved, Investigational
LorpiprazoleThe serum concentration of Prednisone can be increased when it is combined with Lorpiprazole.Approved
LosartanThe serum concentration of Prednisone can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Prednisone.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Prednisone.Approved, Investigational
LuliconazoleThe serum concentration of Prednisone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Prednisone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Prednisone.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Prednisone.Illicit, Investigational, Withdrawn
MagaldrateThe bioavailability of Prednisone can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium carbonateThe bioavailability of Prednisone can be decreased when combined with Magnesium carbonate.Approved, Investigational
Magnesium hydroxideThe bioavailability of Prednisone can be decreased when combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe bioavailability of Prednisone can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Prednisone can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Prednisone.Approved
Magnesium silicateThe bioavailability of Prednisone can be decreased when combined with Magnesium silicate.Approved
Magnesium TrisilicateThe bioavailability of Prednisone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Prednisone is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Prednisone.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Prednisone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Prednisone.Approved
MefloquineThe risk or severity of adverse effects can be increased when Prednisone is combined with Mefloquine.Approved, Investigational
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Prednisone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Prednisone is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Prednisone.Approved
MesterolonePrednisone may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Prednisone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Prednisone.Approved, Investigational, Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Prednisone.Experimental
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Prednisone.Approved
MethallenestrilThe serum concentration of Prednisone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Prednisone is combined with Methanesulfonyl Fluoride.Investigational
MethimazoleThe risk or severity of adverse effects can be increased when Prednisone is combined with Methimazole.Approved
MethyclothiazidePrednisone may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Prednisone.Approved, Vet Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Prednisone.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Prednisone is combined with Methylprednisolone.Approved, Vet Approved
MethyltestosteronePrednisone may increase the fluid retaining activities of Methyltestosterone.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Prednisone.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Prednisone.Experimental
MetoclopramideThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Prednisone.Approved, Investigational
MetolazonePrednisone may increase the hypokalemic activities of Metolazone.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Prednisone.Experimental
MibefradilThe serum concentration of Prednisone can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Prednisone can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Prednisone.Approved, Experimental
MifepristoneThe therapeutic efficacy of Prednisone can be decreased when used in combination with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Prednisone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Prednisone.Approved
MinaprineThe risk or severity of adverse effects can be increased when Prednisone is combined with Minaprine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Prednisone.Approved, Investigational
MitotaneThe serum concentration of Prednisone can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Prednisone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Prednisone.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Prednisone.Experimental
MorniflumateThe risk or severity of adverse effects can be increased when Prednisone is combined with Morniflumate.Approved
MoxestrolThe serum concentration of Prednisone can be increased when it is combined with Moxestrol.Experimental
MoxifloxacinThe risk or severity of tendinopathy can be increased when Prednisone is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Prednisone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Prednisone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Prednisone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Prednisone.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Prednisone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Prednisone is combined with Nalidixic Acid.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Prednisone.Approved
NandrolonePrednisone may increase the fluid retaining activities of Nandrolone.Experimental, Investigational
Nandrolone decanoatePrednisone may increase the fluid retaining activities of Nandrolone decanoate.Approved, Illicit
NaproxenThe risk or severity of gastrointestinal irritation can be increased when Prednisone is combined with Naproxen.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Prednisone is combined with Natalizumab.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Prednisone.Approved, Investigational
NefazodoneThe serum concentration of Prednisone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Prednisone can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Prednisone is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Prednisone is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Prednisone.Approved, Investigational
NetupitantThe serum concentration of Prednisone can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Prednisone can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Prednisone can be increased when it is combined with Nicardipine.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Prednisone.Approved, Investigational
NicorandilThe risk or severity of adverse effects can be increased when Prednisone is combined with Nicorandil.Approved, Investigational
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Prednisone.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Prednisone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Prednisone.Approved
NiguldipineThe serum concentration of Prednisone can be increased when it is combined with Niguldipine.Experimental
NilotinibThe metabolism of Prednisone can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of gastrointestinal irritation can be increased when Prednisone is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Prednisone.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Prednisone.Approved
NisoldipineThe serum concentration of Prednisone can be increased when it is combined with Nisoldipine.Approved
NitrendipineThe serum concentration of Prednisone can be increased when it is combined with Nitrendipine.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Prednisone.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Prednisone is combined with Norfloxacin.Approved
OcrelizumabOcrelizumab may increase the immunosuppressive activities of Prednisone.Approved, Investigational
OfloxacinThe risk or severity of adverse effects can be increased when Prednisone is combined with Ofloxacin.Approved
OlaparibThe metabolism of Prednisone can be decreased when combined with Olaparib.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Prednisone.Experimental, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Prednisone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Prednisone.Approved
OmeprazoleThe serum concentration of Prednisone can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Ondansetron can be increased when it is combined with Prednisone.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Prednisone.Vet Approved
OsimertinibThe serum concentration of Prednisone can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Prednisone.Approved
OxandrolonePrednisone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Prednisone.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Prednisone is combined with Oxolinic acid.Experimental
OxymetholonePrednisone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Prednisone.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Prednisone.Approved, Vet Approved
PalbociclibThe serum concentration of Prednisone can be increased when it is combined with Palbociclib.Approved, Investigational
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Prednisone.Experimental, Nutraceutical
ParaoxonThe risk or severity of adverse effects can be increased when Prednisone is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Prednisone.Approved
ParoxetineThe serum concentration of Prednisone can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Prednisone.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Prednisone.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when Prednisone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Prednisone is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Prednisone can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Prednisone.Approved, Investigational, Vet Approved, Withdrawn
PeruvosidePeruvoside may decrease the cardiotoxic activities of Prednisone.Experimental
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Prednisone.Approved, Investigational, Withdrawn
PhenobarbitalThe serum concentration of Prednisone can be decreased when it is combined with Phenobarbital.Approved, Investigational
Phenyl aminosalicylateThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Prednisone.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Prednisone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Prednisone.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Prednisone.Approved, Investigational
PhenytoinThe serum concentration of Prednisone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Prednisone is combined with Physostigmine.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Prednisone.Approved, Investigational
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Prednisone.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Prednisone is combined with Pipemidic acid.Experimental
PiretanidePrednisone may increase the hypokalemic activities of Piretanide.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Prednisone.Approved, Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Prednisone is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Prednisone.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Prednisone.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Prednisone.Approved
PitolisantThe serum concentration of Prednisone can be decreased when it is combined with Pitolisant.Approved, Investigational
Polyestradiol phosphateThe serum concentration of Prednisone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazidePrednisone may increase the hypokalemic activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Prednisone is combined with Pomalidomide.Approved
PosaconazoleThe serum concentration of Prednisone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Prednisone.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Prednisone.Experimental, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Prednisone.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisone is combined with Prednisolone.Approved, Vet Approved
PrimidoneThe serum concentration of Prednisone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Prednisone.Experimental
PromestrieneThe serum concentration of Prednisone can be increased when it is combined with Promestriene.Investigational
PromethazineThe serum concentration of Prednisone can be increased when it is combined with Promethazine.Approved, Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Prednisone.Approved, Investigational
PropafenoneThe serum concentration of Prednisone can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Prednisone.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Prednisone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Prednisone.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Prednisone.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Prednisone.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Prednisone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Prednisone.Investigational
PyrantelThe risk or severity of myopathy and weakness can be increased when Pyrantel is combined with Prednisone.Approved, Vet Approved
PyridostigmineThe risk or severity of adverse effects can be increased when Prednisone is combined with Pyridostigmine.Approved, Investigational
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Prednisone.Approved
QuinestrolThe serum concentration of Prednisone can be increased when it is combined with Quinestrol.Approved
QuinethazonePrednisone may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Prednisone is combined with Rabies virus inactivated antigen, A.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Prednisone.Approved, Investigational
RanitidineThe serum concentration of Prednisone can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Prednisone.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Prednisone.Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Prednisone.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Prednisone.Approved, Experimental, Investigational
RifabutinThe serum concentration of Prednisone can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Prednisone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Prednisone can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Prednisone.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Prednisone.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Prednisone is combined with Rindopepimut.Investigational
RitonavirThe serum concentration of Prednisone can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Prednisone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Prednisone.Approved, Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Prednisone.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Prednisone.Approved, Investigational
RosoxacinThe risk or severity of adverse effects can be increased when Prednisone is combined with Rosoxacin.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Prednisone is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Prednisone is combined with Rubella virus vaccine.Approved, Investigational
RucaparibThe metabolism of Prednisone can be decreased when combined with Rucaparib.Approved, Investigational
RufloxacinThe risk or severity of adverse effects can be increased when Prednisone is combined with Rufloxacin.Experimental
SalbutamolThe risk or severity of hypokalemia can be increased when Prednisone is combined with Salbutamol.Approved, Vet Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Prednisone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Prednisone.Approved, Investigational, Vet Approved
SalmeterolThe risk or severity of hypokalemia can be increased when Prednisone is combined with Salmeterol.Approved
Salmonella typhi ty2 vi polysaccharide antigenThe risk or severity of adverse effects can be increased when Prednisone is combined with Salmonella typhi ty2 vi polysaccharide antigen.Approved
Salmonella typhi Ty21a live antigenThe risk or severity of adverse effects can be increased when Prednisone is combined with Salmonella typhi ty21a live antigen.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Prednisone.Approved
SaquinavirThe serum concentration of Prednisone can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Prednisone can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Prednisone.Approved
SecoisolariciresinolThe serum concentration of Prednisone can be increased when it is combined with Secoisolariciresinol.Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Prednisone is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Prednisone.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Prednisone.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Prednisone.Investigational
SildenafilThe metabolism of Prednisone can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Prednisone.Approved
SiltuximabThe serum concentration of Prednisone can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Prednisone can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Prednisone.Approved
SitafloxacinThe risk or severity of adverse effects can be increased when Prednisone is combined with Sitafloxacin.Experimental, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Prednisone.Approved, Investigational
Sodium bicarbonateThe bioavailability of Prednisone can be decreased when combined with Sodium bicarbonate.Approved
SomatotropinThe therapeutic efficacy of Prednisone can be decreased when used in combination with Somatotropin.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Prednisone.Investigational
SparfloxacinThe risk or severity of adverse effects can be increased when Prednisone is combined with Sparfloxacin.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Prednisone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Prednisone.Investigational
St. John's WortThe serum concentration of Prednisone can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanolonePrednisone may increase the fluid retaining activities of Stanolone.Illicit, Investigational
StanozololPrednisone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Prednisone can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Prednisone is combined with Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Prednisone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of gastrointestinal irritation can be increased when Prednisone is combined with Sulindac.Approved, Investigational
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Prednisone.Approved, Investigational
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Prednisone.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Prednisone.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Prednisone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Prednisone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Prednisone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Prednisone is combined with Tacrine.Investigational, Withdrawn
TacrolimusTacrolimus may increase the immunosuppressive activities of Prednisone.Approved, Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Prednisone is combined with Talniflumate.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Prednisone.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Prednisone is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Prednisone.Approved, Withdrawn
TelithromycinThe serum concentration of Prednisone can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Prednisone is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Prednisone.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Prednisone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Prednisone.Vet Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Prednisone.Experimental
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Prednisone.Approved
TesamorelinThe serum concentration of the active metabolites of Prednisone can be reduced when Prednisone is used in combination with Tesamorelin resulting in a loss in efficacy.Approved, Investigational
TestosteronePrednisone may increase the fluid retaining activities of Testosterone.Approved, Investigational
Testosterone cypionatePrednisone may increase the fluid retaining activities of Testosterone cypionate.Approved
Testosterone enanthatePrednisone may increase the fluid retaining activities of Testosterone enanthate.Approved
Testosterone propionatePrednisone may increase the fluid retaining activities of Testosterone propionate.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoatePrednisone may increase the fluid retaining activities of Testosterone undecanoate.Approved, Investigational
TetracyclineThe serum concentration of Tetracycline can be increased when it is combined with Prednisone.Approved, Vet Approved
TetrandrineThe risk or severity of adverse effects can be increased when Prednisone is combined with Tetrandrine.Experimental
TG4010The risk or severity of adverse effects can be increased when Prednisone is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Prednisone.Approved
TiboloneThe serum concentration of Prednisone can be increased when it is combined with Tibolone.Approved, Investigational
TiclopidineThe metabolism of Prednisone can be decreased when combined with Ticlopidine.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Prednisone.Investigational
TocilizumabThe serum concentration of Prednisone can be decreased when it is combined with Tocilizumab.Approved
TofacitinibPrednisone may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Prednisone.Approved, Investigational
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Prednisone.Approved, Investigational
Tolfenamic AcidThe risk or severity of gastrointestinal irritation can be increased when Prednisone is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Prednisone.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Prednisone.Approved
TopiramateThe serum concentration of Topiramate can be increased when it is combined with Prednisone.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Prednisone.Approved, Investigational
TorasemidePrednisone may increase the hypokalemic activities of Torasemide.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Prednisone.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Prednisone is combined with Triamcinolone.Approved, Vet Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Prednisone.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Prednisone is combined with Trichlorfon.Vet Approved
TrichlormethiazidePrednisone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Prednisone.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Prednisone.Investigational, Withdrawn
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Prednisone.Approved
TromethamineThe bioavailability of Prednisone can be decreased when combined with Tromethamine.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Prednisone is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Prednisone is combined with Tubocurarine.Approved
Typhoid VaccineThe risk or severity of adverse effects can be increased when Prednisone is combined with Typhoid Vaccine.Approved
TyrothricinThe risk or severity of adverse effects can be increased when Prednisone is combined with Tyrothricin.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Prednisone.Approved, Investigational, Withdrawn
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Prednisone is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
VecuroniumThe risk or severity of myopathy and weakness can be increased when Vecuronium is combined with Prednisone.Approved
VemurafenibThe serum concentration of Prednisone can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Prednisone.Approved
VerapamilThe serum concentration of Prednisone can be increased when it is combined with Verapamil.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Prednisone.Approved, Investigational
VincristineThe excretion of Vincristine can be decreased when combined with Prednisone.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Prednisone.Approved, Investigational
VoriconazoleThe serum concentration of Prednisone can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinPrednisone may increase the anticoagulant activities of Warfarin.Approved
Yellow Fever VaccineThe risk or severity of adverse effects can be increased when Prednisone is combined with Yellow Fever Vaccine.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Prednisone.Approved, Investigational
ZeranolThe serum concentration of Prednisone can be increased when it is combined with Zeranol.Vet Approved
ZidovudineThe risk or severity of adverse effects can be increased when Prednisone is combined with Zidovudine.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Prednisone.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Prednisone can be decreased when combined with Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Prednisone.Withdrawn
Food Interactions
  • Avoid alcohol.
  • Avoid taking with grapefruit juice.
  • Take with food to reduce irritation.
  • When Rayos, the delayed-release tablet, is taken without food, Cmax and bioavailability were lower compared to the fed state.

References

Synthesis Reference

Jean Buendia, Michel Vivat, "Process for the production of prednisone 17.21-diacylates." U.S. Patent US4601854, issued May, 1982.

US4601854
General References
Not Available
External Links
Human Metabolome Database
HMDB0014773
KEGG Drug
D00473
KEGG Compound
C07370
PubChem Compound
5865
PubChem Substance
46508166
ChemSpider
5656
ChEBI
8382
ChEMBL
CHEMBL635
Therapeutic Targets Database
DAP001041
PharmGKB
PA451100
HET
PDN
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Prednisone
ATC Codes
H02AB07 — PrednisoneA07EA03 — Prednisone
AHFS Codes
  • 68:04.00 — Adrenals
MSDS
Download (132 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Post Transplant Lymphoproliferative Disorder / Primary Mediastinal (Thymic) Large B-cell Lymphoma1
0CompletedTreatmentNonneoplastic Condition1
0Not Yet RecruitingBasic ScienceAtherosclerosis / Diabetes Mellitus (DM) / Dyslipidemias1
0RecruitingTreatmentAdenocarcinoma of the Prostate / Advanced Prostate Cancer / Prostate Cancer / Stage IV Prostate Cancer1
0RecruitingTreatmentAdvanced B-cell Lymphoid Malignancies1
1Active Not RecruitingOtherProstate Cancer1
1Active Not RecruitingTreatmentAIDS Related Non-Hodgkin Lymphoma / AIDS-Related Burkitt Lymphoma / AIDS-Related Diffuse Large B-cell Lymphoma / AIDS-Related Plasmablastic Lymphoma / AIDS-Related Primary Effusion Lymphoma / Human Immunodeficiency Virus (HIV) Infections1
1Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1Active Not RecruitingTreatmentFollicular Lymphoma (FL) / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
1Active Not RecruitingTreatmentLung Cancers / Metastatic Cancers1
1Active Not RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer / Metastatic Castration-Resistant Prostate Cancer (mCRPC) / Prostatic Neoplasms1
1Active Not RecruitingTreatmentMultiple Myeloma (MM)1
1Active Not RecruitingTreatmentProstate Cancer1
1CompletedNot AvailableHealthy Adults1
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of Isavuconazole / Pharmacokinetics of Prednisolone1
1CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedDiagnosticAllergic Rhinitis (AR)1
1CompletedDiagnosticAsthma Bronchial1
1CompletedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Precancerous/Nonmalignant Condition1
1CompletedTreatmentAsthma Bronchial2
1CompletedTreatmentCancer, Advanced1
1CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
1CompletedTreatmentDisseminated Sclerosis1
1CompletedTreatmentDrug Interactions1
1CompletedTreatmentHealthy Volunteers3
1CompletedTreatmentLeukemias / Malignant Lymphomas1
1CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
1CompletedTreatmentLymphoma, Large-Cell, Anaplastic / Lymphoma, NK-cell / T-Cell Lymphomas1
1CompletedTreatmentMalignant Lymphomas2
1CompletedTreatmentMalignant Lymphomas / Neoplasms / Neoplasms Metastasis1
1CompletedTreatmentMalignant Lymphomas / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentMetastatic Castration Resistant Prostate Cancer1
1CompletedTreatmentNeoplasms1
1CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)2
1CompletedTreatmentPeripheral T-Cell Lymphoma (PTCL)1
1CompletedTreatmentProstate Cancer2
1CompletedTreatmentProstate Neoplasms2
1CompletedTreatmentRheumatoid Arthritis1
1Not Yet RecruitingTreatmentB-cell Acute Lymphoblastic Leukemia / Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis / Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL1
1Not Yet RecruitingTreatmentPeripheral T-Cell Lymphoma (PTCL)1
1RecruitingBasic ScienceHealthy Volunteers1
1RecruitingOtherGlucocorticoids Toxicity / Glucose tolerance impaired1
1RecruitingTreatmentAcute Leukemias of Ambiguous Lineage / B-cell Adult Acute Lymphoblastic Leukemia / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Burkitt Lymphoma1
1RecruitingTreatmentAnn Arbor Stage II Diffuse Large B-Cell Lymphoma / Ann Arbor Stage III Diffuse Large B-Cell Lymphoma / Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma / CD20 Negative / CD20 Positive / HIV Positivity / Human Immunodeficiency Virus Positive / Lymphoma, AIDS Related / Stage II Diffuse Large B-Cell Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma1
1RecruitingTreatmentBurkitt's Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Malignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)1
1RecruitingTreatmentCancer, Breast / Prostate Cancer1
1RecruitingTreatmentComposite Lymphoma / Grade 3b Follicular Lymphoma / Stage I Diffuse Large B-Cell Lymphoma / Stage I Follicular Lymphoma / Stage II Diffuse Large B-Cell Lymphoma / Stage II Follicular Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage III Follicular Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma / Stage IV Follicular Lymphoma1
1RecruitingTreatmentCongenital Hypoplastic Anemia1
1RecruitingTreatmentFollicular Lymphoma (FL) / Lymphoma, B-Cell / Non-Hodgkin's Lymphoma (NHL)1
1RecruitingTreatmentHigh Grade B-cell Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
1RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer / Prostatic Neoplasms1
1RecruitingTreatmentMetastatic Hormone Refractory Prostate Cancer1
1RecruitingTreatmentProstatic Neoplasms1
1RecruitingTreatmentRenal Transplanted Recipients / Transplantation, Kidney / Transplantation, Renal1
1RecruitingTreatmentStatus Asthmaticus1
1RecruitingTreatmentTransplantation, Liver1
1RecruitingTreatmentTumors, Solid1
1TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia, Lymphoblastic, Acute, T Cell / Lymphoblastic Leukemia, Acute, Childhood1
1TerminatedTreatmentBurkitt's Lymphoma / Follicular Lymphoma (FL) / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
1TerminatedTreatmentProstate Cancer1
1TerminatedTreatmentProstate Cancer / Prostate Cancer Metastatic Disease / Urologic Neoplasms1
1Unknown StatusTreatmentProstate Cancer2
1WithdrawnTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1WithdrawnTreatmentCancers1
1WithdrawnTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2Active Not RecruitingTreatmentAIDS-Related Diffuse Large Cell Lymphoma / AIDS-Related Plasmablastic Lymphoma / AIDS-Related Primary Effusion Lymphoma / CD20 Positive / Grade 3b Follicular Lymphoma / Human Immunodeficiency Virus (HIV) Infections / Plasmablastic Lymphoma / Primary Effusion Lymphomas / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Diffuse Large B-Cell Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage II Contiguous Adult Diffuse Large Cell Lymphoma / Stage II Diffuse Large B-Cell Lymphoma / Stage II Grade 3 Contiguous Follicular Lymphoma / Stage II Grade 3 Non-Contiguous Follicular Lymphoma / Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma / Stage IV Grade 3 Follicular Lymphoma1
1, 2Active Not RecruitingTreatmentAdenocarcinoma of the Prostate / Hormone-Resistant Prostate Cancer / Recurrent Prostate Cancer / Stage IV Prostate Cancer1
1, 2Active Not RecruitingTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Anaplastic Large Cell Lymphoma, ALK-Positive / Hepatosplenic T-Cell Lymphoma / Peripheral T-Cell Lymphoma, Not Otherwise Specified / Stage II Angioimmunoblastic T-cell Lymphoma / Stage II Enteropathy-Associated T-Cell Lymphoma / Stage III Angioimmunoblastic T-cell Lymphoma / Stage III Enteropathy-Associated T-Cell Lymphoma / Stage IV Angioimmunoblastic T-cell Lymphoma / Stage IV Enteropathy-Associated T-Cell Lymphoma1
1, 2Active Not RecruitingTreatmentDiffuse Large B-Cell Lymphoma, Lymphoma Follicular / Diffuse Large B-Cell Lymphoma, Lymphoma, Follicular1
1, 2Active Not RecruitingTreatmentLymphoma, B-Cell, Non-Hodgkin's Lymphoma / Non Hodgkin Lymphoma (NHL)1
1, 2Active Not RecruitingTreatmentLymphoma, Hodgkins1
1, 2Active Not RecruitingTreatmentMalignant Lymphomas1
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM)1
1, 2Active Not RecruitingTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1, 2Active Not RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
1, 2Active Not RecruitingTreatmentProstate Cancer3
1, 2Active Not RecruitingTreatmentProstatic Neoplasms1
1, 2Active Not RecruitingTreatmentStage II Contiguous Adult Diffuse Large Cell Lymphoma / Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
1, 2CompletedTreatmentAdenocarcinoma of the Prostate / Hormone-Resistant Prostate Cancer / Recurrent Prostate Cancer / Stage IV Prostate Cancer1
1, 2CompletedTreatmentAdenocarcinoma of the Prostate / Recurrent Prostate Cancer / Stage IV Prostate Cancer1
1, 2CompletedTreatmentAdult T-cell lymphomas/leukaemias1
1, 2CompletedTreatmentCancers / Castrate-resistant Prostate Cancer (CRPC) / Mestastatic Prostate Cancer / Prostate Cancer1
1, 2CompletedTreatmentCastrate-resistant Prostate Cancer (CRPC)1
1, 2CompletedTreatmentFollicular Lymphoma (FL) / Lymphoma, B-Cell1
1, 2CompletedTreatmentHodgkins Disease (HD)1
1, 2CompletedTreatmentHodgkins Disease (HD) / Malignant Lymphomas1
1, 2CompletedTreatmentKidney Diseases / Transplant, Kidney / Transplantation, Kidney / Transplantation, Renal1
1, 2CompletedTreatmentLeukemias1
1, 2CompletedTreatmentLeukemias / Malignant Lymphomas1
1, 2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
1, 2CompletedTreatmentMalignant Lymphomas2
1, 2CompletedTreatmentMalignant Lymphomas / Non Hodgkin Lymphoma (NHL)1
1, 2CompletedTreatmentMetastatic, Androgen Independent Prostate Cancer / Prostate Cancer1
1, 2CompletedTreatmentMultiple Myeloma (MM)5
1, 2CompletedTreatmentPlasma Cell Myeloma1
1, 2CompletedTreatmentProstate Cancer4
1, 2CompletedTreatmentProstate Cancer / Tumors1
1, 2CompletedTreatmentProstatic Neoplasms1
1, 2CompletedTreatmentRecurrent Childhood Acute Lymphoblastic Leukemia1
1, 2Not Yet RecruitingTreatmentAcute T Cell Leukemia1
1, 2RecruitingTreatmentALK- Anaplastic Large Cell Lymphoma (ALCL) / ALK- Anaplastic Largecell Lymphoma (ALCL) / Angioimmunoblastic T-cell Lymphoma (AITL) / Peripheral T-Cell Lymphoma (PTCL) / Peripheral T-cell Lymphomas Not Otherwise Specified (PTCL-NOS) / PTCL-NOS1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
1, 2RecruitingTreatmentAdult Burkitt Lymphoma / B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / MYC Gene Mutation / Plasmablastic Lymphoma1
1, 2RecruitingTreatmentAdult Grade III Lymphomatoid Granulomatosis / B-Cell Chronic Lymphocytic Leukemia / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Progressive Hairy Cell Leukemia, Initial Treatment / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage 0 Chronic Lymphocytic Leukemia / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Small Lymphocytic Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Testicular Lymphoma / Untreated Hairy Cell Leukemia / Waldenström's Macroglobulinemia (WM)1
1, 2RecruitingTreatmentCastration Levels of Testosterone / Castration-Resistant Prostate Carcinoma / Hormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer / Stage IV Prostate Cancer AJCC v71
1, 2RecruitingTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
1, 2RecruitingTreatmentDiamond Blackfan Anemia1
1, 2RecruitingTreatmentDiffuse B-Cell Lymphoma1
1, 2RecruitingTreatmentGiant Cells Arteritis / Temporal Arteritis1
1, 2RecruitingTreatmentHenoch-Schönlein Purpura Nephritis1
1, 2RecruitingTreatmentLymphoma, B-Cell / Primary Effusion Lymphomas1
1, 2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
1, 2RecruitingTreatmentMalignant Lymphomas1
1, 2RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer (mCRPC)1
1, 2RecruitingTreatmentProstate Cancer1
1, 2RecruitingTreatmentT Cell Non-Hodgkin's Lymphoma1
1, 2TerminatedTreatmentAdenocarcinoma of the Prostate / Prostate Cancer / Recurrent Prostate Cancer / Stage I Prostate Cancer / Stage III Prostate Cancer / Stage IV Prostate Cancer1
1, 2TerminatedTreatmentCastrate-resistant Prostate Cancer (CRPC) / Castrate-resistant Prostate Cancer Patients1
1, 2TerminatedTreatmentMalignant Lymphomas1
1, 2TerminatedTreatmentMultiple Myeloma (MM)1
1, 2TerminatedTreatmentPain / Prostate Cancer1
1, 2TerminatedTreatmentProstate Cancer2
1, 2Unknown StatusTreatmentMalignant Lymphomas1
1, 2Unknown StatusTreatmentMultiple Myeloma (MM)1
1, 2WithdrawnTreatmentLarge Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease / Primary Effusion Lymphomas1
1, 2WithdrawnTreatmentLarge-Cell Lymphoma, Diffuse / Lymphoma, Diffuse Large-Cell / Lymphoma, Diffuse Large-Cell B-cell / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
2Active Not RecruitingTreatmentAcute GvHD1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult Acute Lymphoblastic Leukemia in Remission / Adult B Acute Lymphoblastic Leukemia / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Adult L1 Acute Lymphoblastic Leukemia / Adult L2 Acute Lymphoblastic Leukemia / Adult T Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentAdenocarcinoma, Prostate / High Risk Prostate Cancer / Prostate Cancer1
2Active Not RecruitingTreatmentAdenocarcinoma, Prostate / Hormone-Resistant Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
2Active Not RecruitingTreatmentAdvanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma / Non-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentAgnogenic Myeloid Metaplasia1
2Active Not RecruitingTreatmentAnn Arbor Stage II Diffuse Large B-Cell Lymphoma / Ann Arbor Stage III Diffuse Large B-Cell Lymphoma / Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma / CD20 Positive / Stage II Diffuse Large B-Cell Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma1
2Active Not RecruitingTreatmentCastration Levels of Testosterone / Castration-Resistant Prostate Carcinoma / Hormone-Resistant Prostate Cancer / PSA Progression / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer / Stage IV Prostate Cancer AJCC v71
2Active Not RecruitingTreatmentCastration Resistant Prostate Cancer (CRPC)1
2Active Not RecruitingTreatmentCastration-Resistant Prostate Cancer (CRPC)2
2Active Not RecruitingTreatmentCryoglobulinemia / Systemic Vasculitis1
2Active Not RecruitingTreatmentHodgkins Disease (HD)1
2Active Not RecruitingTreatmentHormone-Resistant Prostate Cancer / Recurrent Prostate Cancer / Stage IV Prostate Cancer1
2Active Not RecruitingTreatmentLung Cancers / Melanoma / Renal Cell Adenocarcinoma1
2Active Not RecruitingTreatmentLymphoma, Extranodal NK-T-Cell / T-Cell Lymphomas1
2Active Not RecruitingTreatmentLymphoma, Hodgkins2
2Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)3
2Active Not RecruitingTreatmentLymphoma, Lymphoblastic1
2Active Not RecruitingTreatmentLymphoproliferative Disorders1
2Active Not RecruitingTreatmentMalignant Lymphomas8
2Active Not RecruitingTreatmentMalignant Lymphomas / Nonneoplastic Condition1
2Active Not RecruitingTreatmentMultiple Myeloma (MM)4
2Active Not RecruitingTreatmentMyelodysplastic Syndrome / Smith-Magenis Syndrome1
2Active Not RecruitingTreatmentMyeloproliferative Disorders1
2Active Not RecruitingTreatmentNephritis, Lupus2
2Active Not RecruitingTreatmentPolycythemia Vera (PV) / Thrombocythemia1
2Active Not RecruitingTreatmentProstate Cancer6
2Active Not RecruitingTreatmentProstate Cancer / Prostate Neoplasms / Prostatic Neoplams / Prostatic Neoplasms1
2Active Not RecruitingTreatmentProstatic Neoplasms2
2Active Not RecruitingTreatmentStage II Childhood Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
2Active Not RecruitingTreatmentSystemic Lupus Erythematosus (SLE)1
2Active Not RecruitingTreatmentTransplantation, Kidney1
2CompletedNot AvailableMultiple Myeloma (MM)1
2CompletedDiagnosticMalignant Lymphomas1
2CompletedPreventionChronic Lung Diseases1
2CompletedPreventionSystemic Lupus Erythematosus (SLE)1
2CompletedSupportive CareCancer of the Ovary / Cancer, Breast / Chronic Myeloproliferative Disorders / Gestational Trophoblastic Disease / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Neuroblastomas / Testicular germ cell tumour1
2CompletedSupportive CareCancers1
2CompletedSupportive CareItching1
2CompletedTreatmentAIDS-Associated Nephropathy / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentAIDS-Related Diffuse Large Cell Lymphoma / AIDS-related Immunoblastic Large Cell Lymphoma / AIDS-related Peripheral/Systemic Lymphoma / AIDS-related Small Noncleaved Cell Lymphoma1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2CompletedTreatmentAdenocarcinoma of the Prostate / Recurrent Prostate Cancer / Stage IV Prostate Cancer1
2CompletedTreatmentAdenocarcinoma of the Prostate / Stage IIA Prostate Cancer / Stage IIB Prostate Cancer / Stage III Prostate Cancer / Stage IV Prostate Cancer1
2CompletedTreatmentAgnogenic Myeloid Metaplasia / Myelofibrosis With Myeloid Metaplasia / Myeloid Metaplasia1
2CompletedTreatmentAmyotrophic Lateral Sclerosis (ALS)1
2CompletedTreatmentAnaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Hepatosplenic T-Cell Lymphoma / Peripheral T-Cell Lymphoma (PTCL)1
2CompletedTreatmentAsthma Bronchial1
2CompletedTreatmentAutoimmune Hemolytic Disease (Cold Type) (Warm Type)1
2CompletedTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Lymphoblastic Lymphoma / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentBirdshot Chorioretinopathy / Cystoid Macular Edema / Transient Partial Visual Loss1
2CompletedTreatmentBlood and Marrow Transplant (BMT) / Graft Versus Host Disease (GVHD)1
2CompletedTreatmentBrain and Central Nervous System Tumors1
2CompletedTreatmentCardiovascular Disease (CVD) / Heart Diseases / Myocarditis1
2CompletedTreatmentCastration Resistant Prostate Cancer (CRPC)1
2CompletedTreatmentChildhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Small Noncleaved Cell Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Childhood Small Noncleaved Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Small Noncleaved Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Small Noncleaved Cell Lymphoma / Untreated Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentChronic Graft Versus Host Disease1
2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Hepatitis C Viral Infection / Nonimmune Nonviral Causes of Liver Failure1
2CompletedTreatmentChronic Lung Diseases / Pulmonary Fibrosis / Sarcoidosis1
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias1
2CompletedTreatmentChronic Myeloproliferative Disorders / Secondary Myelofibrosis1
2CompletedTreatmentChronic Renal Failure (CRF) / Transplantation, Kidney1
2CompletedTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
2CompletedTreatmentCrohn's Disease (CD)1
2CompletedTreatmentDisseminated Sclerosis / Relapsing Remitting Multiple Sclerosis (RRMS)1
2CompletedTreatmentEssential Thrombocythemia (ET) / Polycythemia Vera (PV) / Primary Myelofibrosis1
2CompletedTreatmentGastrointestinal Stromal Tumor(GIST)1
2CompletedTreatmentGiant Cell Myocarditis / Myocarditis1
2CompletedTreatmentGiant Cells Arteritis2
2CompletedTreatmentGlomerulonephritis minimal lesion / Systemic Lupus Erythematosus (SLE)1
2CompletedTreatmentGranulomatosis With Polyangiitis / Inflammatory Reaction / Vasculitis1
2CompletedTreatmentHemangiomas1
2CompletedTreatmentHodgkins Disease (HD) / Lymphoma, Hodgkin Disease / Lymphoma, Hodgkins / Malignant Lymphomas1
2CompletedTreatmentHodgkins Disease (HD) / Pediatric1
2CompletedTreatmentHormone Refractory Prostate Cancer1
2CompletedTreatmentHormone Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer1
2CompletedTreatmentHormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Adenocarcinoma1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lymphoma, AIDS Related1
2CompletedTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
2CompletedTreatmentIgA Glomerulonephritis1
2CompletedTreatmentLeukemias7
2CompletedTreatmentLeukemias / Malignant Lymphomas4
2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myleoma / Myelodysplastic Syndrome / Myeloproliferative Disorders1
2CompletedTreatmentLeukemias / Neutropenias / Thrombocytopenias1
2CompletedTreatmentLupus Erythematosus, Systemic / Nephritis, Lupus1
2CompletedTreatmentLymphoma, B-Cell2
2CompletedTreatmentLymphoma, Hodgkins1
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / POOR PROGNOSIS1
2CompletedTreatmentMalignant Lymphomas33
2CompletedTreatmentMalignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm1
2CompletedTreatmentMalignant Lymphomas / Small Intestine Cancer1
2CompletedTreatmentMantle Cell Lymphoma (MCL)1
2CompletedTreatmentMetastatic Castration Resistant Prostate Cancer1
2CompletedTreatmentMetastatic Hormone Refractory Prostate Cancer3
2CompletedTreatmentMultiple Myeloma (MM)9
2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm3
2CompletedTreatmentMyelodysplastic Syndrome1
2CompletedTreatmentMyelodysplastic Syndromes1
2CompletedTreatmentNephritis, Lupus2
2CompletedTreatmentNon-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)1
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)3
2CompletedTreatmentOral Lichen Planus1
2CompletedTreatmentPemphigus Vulgaris (PV)1
2CompletedTreatmentPolymorphism, Genetic / Prostate Cancer1
2CompletedTreatmentProstate Cancer18
2CompletedTreatmentProstate Cancer / Prostate Neoplasms1
2CompletedTreatmentProstate Cancer / Prostatic Neoplasms1
2CompletedTreatmentProstate Neoplasms1
2CompletedTreatmentProstatic Neoplasms3
2CompletedTreatmentRelapsed Follicular Lymphoma1
2CompletedTreatmentRenal Cancers1
2CompletedTreatmentRheumatoid Arthritis3
2CompletedTreatmentSarcomas1
2CompletedTreatmentSciatica1
2CompletedTreatmentSystemic Lupus Erythematosus (SLE)1
2CompletedTreatmentThymoma and Thymic Carcinoma1
2CompletedTreatmentTransplantation, Kidney1
2CompletedTreatmentTransplantation, Liver1
2CompletedTreatmentUntreated T-Cell Angioimmunoblastic Lymphoma1
2CompletedTreatmentUveitis1
2CompletedTreatmentVestibular Diseases / Vestibular Neuronitis1
2Enrolling by InvitationSupportive CareCastration-Resistant Prostate Cancer (CRPC) / Prostate Cancer1
2Enrolling by InvitationTreatmentAcute,Leukemia, Lymphoid1
2Enrolling by InvitationTreatmentAlcoholic Hepatitis (AH)1
2Enrolling by InvitationTreatmentGraft Versus Host Disease (GVHD)1
2Not Yet RecruitingTreatmentAntibody-mediated Rejection / Lung Transplant Rejection1
2Not Yet RecruitingTreatmentB Acute Lymphoblastic Leukemia / B Lymphoblastic Lymphoma / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent B Lymphoblastic Lymphoma / Recurrent T Lymphoblastic Leukemia/Lymphoma / Refractory B Lymphoblastic Lymphoma / Refractory T Lymphoblastic Lymphoma / T Acute Lymphoblastic Leukemia / T Lymphoblastic Lymphoma1
2Not Yet RecruitingTreatmentExperimental Tumor1
2Not Yet RecruitingTreatmentProstate Cancer1
2Not Yet RecruitingTreatmentProstatic Neoplasms1
2RecruitingSupportive CareB-cell Non-Hodgkin's Lymphomas1
2RecruitingTreatmentAIDS-Related Diffuse Large Cell Lymphoma / AIDS-Related Diffuse Mixed Cell Lymphoma / AIDS-Related Diffuse Small Cleaved Cell Lymphoma / AIDS-related Immunoblastic Large Cell Lymphoma / AIDS-Related Lymphoblastic Lymphoma / AIDS-related Peripheral/Systemic Lymphoma / AIDS-related Small Noncleaved Cell Lymphoma / Stage III AIDS-related Lymphoma / Stage IV AIDS-related Lymphoma1
2RecruitingTreatmentALL (Acute Lymphoblastic Leukemia) / B-cell Acute Lymphoblastic Leukemia1
2RecruitingTreatmentAbnormal DNA Repair / Hormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Prostate Cancer Metastatic Castration-Resistant / Stage IV Prostate Cancer1
2RecruitingTreatmentAcute Interstitial Nephritis1
2RecruitingTreatmentAcute Leukemias of Ambiguous Lineage / Childhood B Acute Lymphoblastic Leukemia / KMT2A Gene Rearrangement / Mixed Phenotype Acute Leukemia (MPAL)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative / Philadelphia Chromosome Positive / Recurrent Adult Acute Lymphoblastic Leukemia / Refractory Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias / Lymphoma, Lymphoblastic1
2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Adult Lymphoblastic Lymphoma1
2RecruitingTreatmentAdult Acute Lymphoblastic Leukemia / Adult Lymphoblastic Lymphoma / CD20 Positive / Philadelphia Chromosome Positive1
2RecruitingTreatmentAdult T-Cell Leukemia/Lymphoma / Anaplastic Large Cell Lymphoma, ALK-Negative / Anaplastic Large Cell Lymphoma, ALK-Positive / Angioimmunoblastic T-Cell Lymphoma / CD30-Positive Neoplastic Cells Present / Enteropathy-Associated T-Cell Lymphoma / Hepatosplenic T-Cell Lymphoma / Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Peripheral T-Cell Lymphoma, Not Otherwise Specified / Stage III Anaplastic Large Cell Lymphoma / Stage IV Anaplastic Large Cell Lymphoma1
2RecruitingTreatmentAggressive Non-Hodgkin Lymphoma1
2RecruitingTreatmentAll1
2RecruitingTreatmentAutoimmune Diseases1
2RecruitingTreatmentAutoimmune Diseases / Autoimmune Disorders1
2RecruitingTreatmentCastration Levels of Testosterone / Castration-Resistant Prostate Carcinoma / Metastatic Prostate Carcinoma in the Soft Tissue / Prostate Carcinoma Metastatic in the Bone / PSA Progression / Stage IV Prostate Adenocarcinoma AJCC v7 / Stage IV Prostate Cancer AJCC v71
2RecruitingTreatmentCastration-Resistant Prostate Cancer (CRPC) / Metastatic Castration Resistant Prostate Cancer1
2RecruitingTreatmentClassical Hodgkin Lymphoma1
2RecruitingTreatmentCorticosteroid Resistant (CR) Asthmatics1
2RecruitingTreatmentDiseases of Male Genital Organs / Prostate Cancer1
2RecruitingTreatmentDuchenne's Muscular Dystrophy (DMD)1
2RecruitingTreatmentFocal Segmental Glomerulosclerosis (FSGS) / Transplantation, Kidney1
2RecruitingTreatmentGrade 1 Follicular Lymphoma / Grade 2 Follicular Lymphoma / Grade 3a Follicular Lymphoma / Recurrent Follicular Lymphoma / Refractory Follicular Lymphoma1
2RecruitingTreatmentGraft Versus Host Disease, Acute1
2RecruitingTreatmentHHV-8 / Human Immunodeficiency Virus (HIV) / Lymphoproliferative Disorders / Malignancies1
2RecruitingTreatmentHenoch-Schoenlein Purpura Nephritis2
2RecruitingTreatmentHormone-Resistant Prostate Cancer / Stage IV Prostate Adenocarcinoma1
2RecruitingTreatmentLeukaemia, Lymphoblastic1
2RecruitingTreatmentLeukemias4
2RecruitingTreatmentAdvanced thymic carcinoma / Lung Cancer Metastatic / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancer Small Cell Lung Cancer (SCLC) / Lung Cancers / Pleural Mesotheliomas1
2RecruitingTreatmentLymphoma, Hodgkins2
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)3
2RecruitingTreatmentMalignant Lymphomas1
2RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer1
2RecruitingTreatmentMetastatic Hormone Refractory Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
2RecruitingTreatmentMulticentric Castleman Disease1
2RecruitingTreatmentMultiple Myeloma (MM)3
2RecruitingTreatmentNon-Infectious Uveitis / Noninfectious Uveitis1
2RecruitingTreatmentPeripheral T-Cell Lymphoma (PTCL)1
2RecruitingTreatmentPosttransplant Lymphoproliferative Disorder1
2RecruitingTreatmentPrecursor Cell Lymphoblastic Leukemia-Lymphoma1
2RecruitingTreatmentProstate Cancer10
2RecruitingTreatmentProstate Cancer / Prostate Cancer Aggressiveness1
2RecruitingTreatmentProstatic Neoplasms2
2RecruitingTreatmentStage II Prostate Adenocarcinoma / Stage III Prostate Adenocarcinoma1
2RecruitingTreatmentStage III Prostate Adenocarcinoma / Stage III Prostate Adenocarcinoma AJCC v7 / Stage III Prostate Cancer / Stage III Prostate Cancer AJCC v7 / Stage IV Prostate Adenocarcinoma / Stage IV Prostate Adenocarcinoma AJCC v7 / Stage IV Prostate Cancer / Stage IV Prostate Cancer AJCC v71
2RecruitingTreatmentSudden Sensorineural Hearing Loss (SSNHL)1
2RecruitingTreatmentTransplant, Kidney1
2TerminatedPreventionCryptogenic Organizing Pneumonia / Lung Diseases, Interstitial / Obliterative Bronchiolitis / Respiratory Tract Infections (RTI)1
2TerminatedSupportive CareDiarrhea / Hormone-Resistant Prostate Cancer / Recurrent Prostate Cancer / Stage I Prostate Cancer / Stage IIA Prostate Cancer / Stage IIB Prostate Cancer / Stage III Prostate Cancer / Stage IV Prostate Cancer1
2TerminatedTreatmentAdenocarcinoma of the Prostate / Stage IV Prostate Cancer1
2TerminatedTreatmentAnaplastic Large Cell Lymphoma1
2TerminatedTreatmentCastration Resistant Prostate Cancer (CRPC) / Prostate Cancer / Prostatic Neoplasms1
2TerminatedTreatmentCholesterol Embolism Systemic1
2TerminatedTreatmentChurg-Strauss Syndrome (CSS)1
2TerminatedTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Testicular Lymphoma / Waldenström's Macroglobulinemia (WM)1
2TerminatedTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
2TerminatedTreatmentEnd-Stage Renal Disease (ESRD)1
2TerminatedTreatmentFollicular Lymphoma, Grade 3b / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Transformed Lymphoma / DLBCL1
2TerminatedTreatmentHaemoglobinopathies congenital / Hemoglobin SC Disease / Sickle Cell Disorders / Thalassaemic disorders / Thalassemia Major (TM)1
2TerminatedTreatmentHemangiomas1
2TerminatedTreatmentHodgkins Disease (HD)1
2TerminatedTreatmentHormone Refractory Prostate Cancer1
2TerminatedTreatmentInflammatory Diseases / Polymyalgia Rheumatica1
2TerminatedTreatmentKidney Transplant Recipients1
2TerminatedTreatmentLeukemias1
2TerminatedTreatmentLeukemias / Lymphoma, Lymphoblastic / Malignant Lymphomas / Precursor-B Acute Lymphoblastic Leukemia1
2TerminatedTreatmentLeukemias / Malignant Lymphomas1
2TerminatedTreatmentLymphatic Diseases / Lymphoma, B-Cell1
2TerminatedTreatmentLymphoma, B-Cell / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
2TerminatedTreatmentLymphoma, Hodgkins1
2TerminatedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2TerminatedTreatmentMalignant Lymphomas2
2TerminatedTreatmentMetastatic Castrate-Resistant Prostate Cancer / Prostate Cancer / PsA1
2TerminatedTreatmentMetastatic Hormone Refractory Prostate Cancer1
2TerminatedTreatmentMetastatic Renal Cancer1
2TerminatedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentPlasma Cell Myeloma1
2TerminatedTreatmentPolymyalgia Rheumatica1
2TerminatedTreatmentProstate Cancer3
2TerminatedTreatmentRheumatoid Arthritis2
2TerminatedTreatmentT-Cell Non-Hodgkin Lymphoma1
2TerminatedTreatmentTransplantation, Kidney1
2Unknown StatusNot AvailableHepatitis C Viral Infection1
2Unknown StatusTreatmentAnemia, Hemolytic, Autoimmune / Anemias / Autoimmune Diseases / Hematologic Diseases / Hemolysis / Hemolytic Anemia / Immune System Diseases / Pathologic Processes1
2Unknown StatusTreatmentCellulitis / Erysipelas1
2Unknown StatusTreatmentHIV-associated Hodgkin Lymphoma1
2Unknown StatusTreatmentLeukemias1
2Unknown StatusTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2Unknown StatusTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Non-Hodgkin's Lymphoma (NHL)1
2Unknown StatusTreatmentMalignant Lymphomas6
2Unknown StatusTreatmentMyelodysplastic Syndrome1
2Unknown StatusTreatmentNHL With Hemophagocytic Lymphohistiocytosis1
2Unknown StatusTreatmentRenal Insufficiency,Chronic / Transplantation, Liver1
2Unknown StatusTreatmentRetroperitoneal Fibrosis1
2WithdrawnBasic SciencePost-menopausal ER+ Stage I-IIIA Primary Operable Breast Cancer1
2WithdrawnSupportive CareDuchenne's Muscular Dystrophy (DMD)1
2WithdrawnTreatmentAdenocarcinoma of the Prostate / Prostate Cancer / Stage I Prostate Cancer / Stage II Prostate Cancer1
2WithdrawnTreatmentB-cell Adult Acute Lymphoblastic Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2WithdrawnTreatmentCastrate-resistant Metastatic Prostate Cancer1
2WithdrawnTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
2WithdrawnTreatmentFibrolamellar Hepatocellular Carcinoma / Hepatocellular Carcinoma (Fibrolamellar Variant) / Hepatocellular,Carcinoma1
2WithdrawnTreatmentLocalized Prostate Cancer / Prostate Cancer1
2WithdrawnTreatmentMalignant Lymphomas3
2WithdrawnTreatmentProstate Cancer3
2, 3Active Not RecruitingTreatmentChildhood B Acute Lymphoblastic Leukemia / Childhood Burkitt Leukemia / Childhood Diffuse Large Cell Lymphoma / Mediastinal (Thymic) Large B-Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma1
2, 3Active Not RecruitingTreatmentChronic Graft Versus Host Disease1
2, 3CompletedTreatmentAcute Exacerbation of Chronic Obstructive Pulmonary Disease1
2, 3CompletedTreatmentAcute Urticaria1
2, 3CompletedTreatmentAdult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
2, 3CompletedTreatmentAllergies1
2, 3CompletedTreatmentAtherosclerosis / Coronary Artery Disease / Ischaemic Heart Diseases1
2, 3CompletedTreatmentGranulomatosis With Polyangiitis / Microscopic Polyangiitis / Vasculitis1
2, 3CompletedTreatmentHepatitis, Autoimmune1
2, 3CompletedTreatmentImmune Thrombocytopenic Purpura ( ITP )1
2, 3CompletedTreatmentLupus Erythematosus, Systemic1
2, 3CompletedTreatmentOptic Neuritis1
2, 3CompletedTreatmentProstate Cancer1
2, 3CompletedTreatmentRheumatoid Arthritis1
2, 3Not Yet RecruitingTreatmentAnti-Inflammatory Agents / Takayasu's Disease1
2, 3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Lymphoblastic Lymphoma1
2, 3RecruitingTreatmentBell's Palsy / Facial Nerve Paresis1
2, 3RecruitingTreatmentCroticosteroid Therapy / Idiopathic Thrombocytopenic Purpura (ITP)1
2, 3RecruitingTreatmentHeart Failure, Hyperuricemia1
2, 3RecruitingTreatmentHeart Failure, Unspecified / Hyperuricemia1
2, 3RecruitingTreatmentLangerhans Cell Histiocytosis (LCH)1
2, 3RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2, 3RecruitingTreatmentMature B-Cell Lymphoma1
2, 3RecruitingTreatmentMature B-cell Non-Hodgkin Lymphoma1
2, 3SuspendedTreatmentCongestive Heart Failure (CHF)1
2, 3TerminatedTreatmentDermatomyositis1
2, 3TerminatedTreatmentHemophilia A1
2, 3TerminatedTreatmentMalignant Lymphomas1
2, 3Unknown StatusTreatmentIgG4-related Disease1
2, 3Unknown StatusTreatmentLeukemias1
3Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3Active Not RecruitingTreatmentAdenocarcinoma of the Prostate / Hormone-Resistant Prostate Cancer / Recurrent Prostate Cancer / Stage IV Prostate Cancer1
3Active Not RecruitingTreatmentAnaplastic Large-Cell Lymphoma / Lymphoma, Large-Cell, Anaplastic / Non-Hodgkin's Lymphoma (NHL) / T-Cell Lymphomas1
3Active Not RecruitingTreatmentB-cell Childhood Acute Lymphoblastic Leukemia / Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia / L1 Childhood Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentChildhood Favorable Prognosis Hodgkin Lymphoma / Childhood Lymphocyte Depletion Hodgkin Lymphoma / Childhood Mixed Cellularity Hodgkin Lymphoma / Childhood Nodular Sclerosis Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma1
3Active Not RecruitingTreatmentChildhood Nodular Lymphocyte Predominant Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
3Active Not RecruitingTreatmentDuchenne's Muscular Dystrophy (DMD)1
3Active Not RecruitingTreatmentFailing Renal Allograft / Transplant, Kidney1
3Active Not RecruitingTreatmentFollicular Lymphoma (FL) / Lymphoplasmacytic Lymphoma / Marginal Zone Lymphoma / Small Lymphocytic Lymphoma (SLL)1
3Active Not RecruitingTreatmentGiant Cells Arteritis1
3Active Not RecruitingTreatmentLarge B Cell Lymphoma1
3Active Not RecruitingTreatmentLeukemias1
3Active Not RecruitingTreatmentLymphoma, Hodgkins1
3Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
3Active Not RecruitingTreatmentMalignant Lymphomas10
3Active Not RecruitingTreatmentMalignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)1
3Active Not RecruitingTreatmentMantle Cell Lymphoma (MCL)1
3Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC) / Metastatic Castration Resistant Prostate Cancer1
3Active Not RecruitingTreatmentMultiple Myeloma (MM)3
3Active Not RecruitingTreatmentMultiple Myeloma (MM) / Newly Diagnosed Patients1
3Active Not RecruitingTreatmentNephritis, Lupus2
3Active Not RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
3Active Not RecruitingTreatmentPlasma Cell Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3Active Not RecruitingTreatmentProstate Cancer4
3Active Not RecruitingTreatmentProstate Neoplasms1
3Active Not RecruitingTreatmentProstatic Neoplasms2
3Active Not RecruitingTreatmentThrombotic Thrombocytopenic Purpura (TTP)1
3Active Not RecruitingTreatmentUveitis1
3CompletedPreventionChronic Renal Failure (CRF)1
3CompletedPreventionHuman Immunodeficiency Virus (HIV) / Immune Reconstitution Inflammatory Syndrome / Tuberculosis1
3CompletedSupportive CareCardiac Toxicity / Leukemias / Malignant Lymphomas1
3CompletedSupportive CareGraft Versus Host Disease (GVHD)2
3CompletedSupportive CareGraft Versus Host Disease (GVHD) / Recurrent Adult Acute Lymphoblastic Leukemia1
3CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Undifferentiated Leukemia (AUL) / Childhood T Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult T Acute Lymphoblastic Leukemia / Ann Arbor Stage II Adult T-Cell Leukemia/Lymphoma / Ann Arbor Stage II Childhood Lymphoblastic Lymphoma / Ann Arbor Stage II Contiguous Adult Lymphoblastic Lymphoma / Ann Arbor Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Ann Arbor Stage III Adult Lymphoblastic Lymphoma / Ann Arbor Stage III Adult T-Cell Leukemia/Lymphoma / Ann Arbor Stage III Childhood Lymphoblastic Lymphoma / Ann Arbor Stage IV Adult Lymphoblastic Lymphoma / Ann Arbor Stage IV Adult T-Cell Leukemia/Lymphoma / Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma / Childhood T Acute Lymphoblastic Leukemia / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / T Acute Lymphoblastic Leukemia / T Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3CompletedTreatmentAdenocarcinoma of the Prostate / Hormone-Resistant Prostate Cancer / Recurrent Prostate Cancer / Stage IV Prostate Cancer1
3CompletedTreatmentAllergies / Conjunctivitis / Rhinitis / Rhinoconjunctivitis2
3CompletedTreatmentAlzheimer's Disease (AD)1
3CompletedTreatmentAsthma Bronchial5
3CompletedTreatmentCardiac Toxicity / Malignant Lymphomas1
3CompletedTreatmentCastration Resistant Prostate Cancer (CRPC) / Pain / Prostate Cancer / Prostatic Neoplasms1
3CompletedTreatmentChildhood Lymphocyte-Depleted Classical Hodgkin Lymphoma / Childhood Mixed Cellularity Classical Hodgkin Lymphoma / Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma / Childhood Nodular Sclerosis Classical Hodgkin Lymphoma / Malignant Lymphomas / Stage I Childhood Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
3CompletedTreatmentChronic Kidney Disease (CKD) / IgA Nephropathy1
3CompletedTreatmentCommunity Acquired Pneumonia (CAP)1
3CompletedTreatmentCrohn's Disease (CD)1
3CompletedTreatmentDemyelinating Polyneuropathy1
3CompletedTreatmentDermatomyositis / Polymyositis1
3CompletedTreatmentDisseminated Neuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Regional Neuroblastoma / Stage 4S Neuroblastoma1
3CompletedTreatmentDuchenne's Muscular Dystrophy (DMD)2
3CompletedTreatmentElderly Patients (>65 Years) / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
3CompletedTreatmentGlomerulonephritis minimal lesion1
3CompletedTreatmentHeart Diseases / Heart Transplantation1
3CompletedTreatmentHeart Failure, Unspecified1
3CompletedTreatmentHormone Refractory Prostate Cancer / Prostate Cancer1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
3CompletedTreatmentKidney Diseases1
3CompletedTreatmentLeukemia, Myelocytic, Acute1
3CompletedTreatmentLeukemias8
3CompletedTreatmentLeukemias / Malignant Lymphomas3
3CompletedTreatmentLymphoma, B-Cell / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
3CompletedTreatmentLymphoma, Hodgkins3
3CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
3CompletedTreatmentMalignant Lymphomas13
3CompletedTreatmentMantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL)1
3CompletedTreatmentMetastatic Cancers / Prostate Cancer1
3CompletedTreatmentMultiple Myeloma (MM)6
3CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm2
3CompletedTreatmentNeoplasms / Prostatic Neoplasms1
3CompletedTreatmentNephritis, Lupus1
3CompletedTreatmentNewly Diagnosed Multiple Myeloma1
3CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)2
3CompletedTreatmentNonneoplastic Condition1
3CompletedTreatmentOrgan Transplantation, Renal Transplantation1
3CompletedTreatmentPain / Prostate Cancer / Quality of Life1
3CompletedTreatmentPerennial Allergic Rhinitis (PAR)1
3CompletedTreatmentPneumonia1
3CompletedTreatmentPolyps, Nasal1
3CompletedTreatmentProstate Cancer11
3CompletedTreatmentProstate Neoplasms1
3CompletedTreatmentProstatic Neoplasms3
3CompletedTreatmentPurpura, Thrombocytopenic, Idiopathic1
3CompletedTreatmentSarcoidosis, Pulmonary1
3CompletedTreatmentSciatica1
3CompletedTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3CompletedTreatmentStage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Small Lymphocytic Lymphoma1
3CompletedTreatmentSudden Deafness1
3CompletedTreatmentTransplantation, Kidney2
3CompletedTreatmentTransplantation, Renal1
3CompletedTreatmentUveitis2
3No Longer AvailableNot AvailableMultiple Myeloma (MM)1
3Not Yet RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Lymphocytic Leukemia (ALL) / Leukaemia, Lymphoblastic / Leukemia, Lymphoblastic, Acute, Philadelphia-Positive / Lymphoblastic Leukemia, Acute, Adult / Ph1 Chromosome1
3Not Yet RecruitingTreatmentCardiac Sarcoidosis / Sarcoidosis1
3Not Yet RecruitingTreatmentChondrocalcinosis pyrophosphate1
3Not Yet RecruitingTreatmentCongenital Adrenal Hyperplasia (CAH)1
3Not Yet RecruitingTreatmentGiant Cells Arteritis1
3Not Yet RecruitingTreatmentGlomerulonephritis minimal lesion / Glomerulosclerosis, Focal Segmental / Idiopathic Nephrotic Syndrome1
3Not Yet RecruitingTreatmentPeripheral T Cell Lymphoma (PTCL)1
3Not Yet RecruitingTreatmentPeripheral T-Cell Lymphoma (PTCL)1
3Not Yet RecruitingTreatmentPolymyalgia Rheumatica1
3RecruitingOtherAsthma Bronchial1
3RecruitingTreatmentANCA-Associated Vasculitis (AAV)1
3RecruitingTreatmentAcute Graft-Versus-Host Disease / Graft-versus-host Disease (GVHD)1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult B Acute Lymphoblastic Leukemia / B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative / BCR/ABL1 Fusion Protein Negative / Untreated Adult Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / BCR-ABL1 Fusion Protein Expression / Minimal Residual Disease / Philadelphia Chromosome Positive / T Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Osteonecrosis / Pain / Ph-Like Acute Lymphoblastic Leukemia / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAdult Immune Thrombocytopenia (ITP) / Dapsone1
3RecruitingTreatmentAnn Arbor Stage IIB Hodgkin Lymphoma / Ann Arbor Stage IIIB Hodgkin Lymphoma / Ann Arbor Stage IV Hodgkin Lymphoma / Ann Arbor Stage IVA Hodgkin Lymphoma / Ann Arbor Stage IVB Hodgkin Lymphoma / Childhood Hodgkin Lymphoma / Classic Hodgkin Lymphoma / Classical Hodgkin Lymphoma / Stage IIB Hodgkin Lymphoma / Stage IIIB Hodgkin Lymphoma / Stage IV Hodgkin Lymphoma / Stage IVA Hodgkin Lymphoma / Stage IVB Hodgkin Lymphoma1
3RecruitingTreatmentB Acute Lymphoblastic Leukemia / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Osteonecrosis / Pain / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentChronic Graft Versus Host Disease1
3RecruitingTreatmentChronic Inflammation / Cognitive Impairments / Pain, Chronic / Tiredness1
3RecruitingTreatmentChronic Rhinosinusitis / Sinusitis1
3RecruitingTreatmentClassical Hodgkin Lymphoma2
3RecruitingTreatmentCongenital Adrenal Hyperplasia (CAH)1
3RecruitingTreatmentCystic Fibrosis Pulmonary Exacerbation1
3RecruitingTreatmentFollicular Lymphoma (FL)1
3RecruitingTreatmentFollicular Non-Hodgkin's Lymphoma1
3RecruitingTreatmentGlomerulonephritis minimal lesion1
3RecruitingTreatmentGranulomatosis With Polyangiitis1
3RecruitingTreatmentGranulomatosis With Polyangiitis / Vasculitis1
3RecruitingTreatmentLangerhans Cell Histiocytosis (LCH)1
3RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)7
3RecruitingTreatmentMalignant Lymphomas1
3RecruitingTreatmentMetastatic Hormone Refractory Prostate Cancer1
3RecruitingTreatmentMultiple Myeloma (MM)1
3RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
3RecruitingTreatmentProstate Cancer1
3RecruitingTreatmentSystemic Lupus Erythematosus (SLE)1
3RecruitingTreatmentUlcerative Colitis (UC)1
3SuspendedTreatmentMalignant Lymphomas1
3TerminatedHealth Services ResearchFollicular Lymphoma (FL)1
3TerminatedTreatmentANCA Associated Systemic Vasculitis Including Wegener’s / Granulomatosis and Microscopic Polyangiitis and / Renal Limited Vasculitis1
3TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3TerminatedTreatmentAtherosclerosis / Renal Failure1
3TerminatedTreatmentCastrate-resistant Prostate Cancer (CRPC) / Hormone Refractory Prostate Cancer1
3TerminatedTreatmentCastration Resistant Prostate Cancer (CRPC) / Pain / Prostate Cancer / Prostatic Neoplasms1
3TerminatedTreatmentDiffuse Large B Cell Lymphoma CD20 Positive / Diffuse Large B Cell Lymphoma CD20+1
3TerminatedTreatmentDuchenne's Muscular Dystrophy (DMD)1
3TerminatedTreatmentGiant Cells Arteritis1
3TerminatedTreatmentGraft Versus Host Disease (GVHD)1
3TerminatedTreatmentImmune Thrombocytopenic Purpura ( ITP )1
3TerminatedTreatmentLymphoma, B Cell1
3TerminatedTreatmentLymphoma, Extranodal NK-T-Cell1
3TerminatedTreatmentMalignant Lymphomas1
3TerminatedTreatmentNephritis, Lupus2
3TerminatedTreatmentNewly Diagnosed, Multiple Myeloma1
3TerminatedTreatmentOcular Myasthenia Gravis1
3TerminatedTreatmentPemphigus1
3TerminatedTreatmentPolymyalgia Rheumatica1
3TerminatedTreatmentProstate Cancer3
3TerminatedTreatmentProstatic Neoplasms2
3Unknown StatusTreatmentBrain and Central Nervous System Tumors1
3Unknown StatusTreatmentChronic Periaortitis / Idiopathic Retroperitoneal Fibrosis / Perianeurysmal Retroperitoneal Fibrosis1
3Unknown StatusTreatmentDisseminated Sclerosis / Optic Neuritis1
3Unknown StatusTreatmentIPI≥2 / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
3Unknown StatusTreatmentLeukemias1
3Unknown StatusTreatmentMalignant Lymphomas7
3Unknown StatusTreatmentMantle Cell Lymphoma (MCL)1
3Unknown StatusTreatmentMultiple Myeloma (MM)1
3Unknown StatusTreatmentMultiple Myeloma and Plasma Cell Neoplasm3
3WithdrawnTreatmentAnemias / Hyper-reactive Malarial Splenomegaly / Plasmodium Infections1
3WithdrawnTreatmentLeukemias1
4Active Not RecruitingBasic ScienceChronic Obstructive Pulmonary Disease (COPD)1
4Active Not RecruitingPreventionAsthma Bronchial / Upper Respiratory Tract Infections1
4Active Not RecruitingPreventionInfections, Cytomegalovirus / Transplantation Infection1
4Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
4Active Not RecruitingTreatmentAcute maxillary sinusitis caused by M. catarrhalis / Chronic Rhinosinusitis / Polyps, Nasal1
4Active Not RecruitingTreatmentGranulomatosis With Polyangiitis / Microscopic Polyangiitis1
4Active Not RecruitingTreatmentProstate Cancer1
4Active Not RecruitingTreatmentTransplantation, Renal1
4Active Not RecruitingTreatmentUlcerative Colitis (UC)1
4CompletedNot AvailableInflammatory Bowel Disease 111
4CompletedNot AvailableMultiple Myeloma (MM)1
4CompletedDiagnosticAdrenal Gland Hypofunction1
4CompletedPreventionAdverse Effects / Transplantation, Kidney1
4CompletedPreventionEsophageal Strictures1
4CompletedPreventionTransplantation, Kidney2
4CompletedPreventionTransplantation, Liver1
4CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)4
4CompletedTreatmentAsthma Acute / Asthma Bronchial / Reactive Airway Exacerbation1
4CompletedTreatmentAsthma Bronchial1
4CompletedTreatmentAsthma Bronchial / Reactive Airways Disease (RAD)1
4CompletedTreatmentBullous Pemphigoid (BP)1
4CompletedTreatmentChronic Kidney Disease (CKD) / Transplantation, Kidney1
4CompletedTreatmentChronic Obstructive (MeSH) / Pulmonary Diseases1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4CompletedTreatmentChronic Renal Failure (CRF) / Renal Insufficiency,Chronic / Transplantation, Kidney1
4CompletedTreatmentComparative Study / Immunosuppressive Agents1
4CompletedTreatmentCroup1
4CompletedTreatmentDisorder Related to Renal Transplantation / Infections, Cytomegalovirus1
4CompletedTreatmentGraft Versus Host Disease (GVHD) / Renal Failure1
4CompletedTreatmentHeart Failure, Unspecified / Hyperuricemia1
4CompletedTreatmentHenoch-Schönlein Purpura Nephritis1
4CompletedTreatmentHepatitis, Autoimmune1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
4CompletedTreatmentJuvenile Chronic Polyarthritis / Juvenile Idiopathic Arthritis (JIA) / Rheumatoid Arthritis, Juvenile1
4CompletedTreatmentKidney Diseases1
4CompletedTreatmentLiver Cirrhosis / Liver Transplant Disorder1
4CompletedTreatmentMetastatic Hormone Refractory Prostate Cancer1
4CompletedTreatmentPolymyalgia Rheumatica1
4CompletedTreatmentProstate Cancer1
4CompletedTreatmentPurpura, Thrombocytopenic, Idiopathic1
4CompletedTreatmentRenal Transplanted Recipients1
4CompletedTreatmentRheumatoid Arthritis2
4CompletedTreatmentTransplantation, Kidney2
4CompletedTreatmentTransplantation, Liver1
4CompletedTreatmentTransplantation, Renal1
4Enrolling by InvitationTreatmentAchalasia1
4Enrolling by InvitationTreatmentEfficacy and Safety / Mycophenolate Mofetil / Neuromyelitis Optica Spectrum Disorders1
4Not Yet RecruitingOtherUlcerative Colitis (UC)1
4Not Yet RecruitingTreatmentNephrotic Syndrome, Minimal Change1
4Not Yet RecruitingTreatmentPneumonia Hospital Acquired1
4Not Yet RecruitingTreatmentSjögren's Syndrome1
4Not Yet RecruitingTreatmentPh+ Acute Lymphoblastic Leukemia1
4RecruitingBasic ScienceBrown Adipose Tissue1
4RecruitingPreventionDisseminated Sclerosis1
4RecruitingPreventionEnd-Stage Renal Disease (ESRD)1
4RecruitingSupportive CareCastration-Resistant Prostatic Cancer / Hormone-Refractory Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
4RecruitingSupportive CareRheumatoid Arthritis1
4RecruitingTreatmentAcute Lymphobkastic Leukemia1
4RecruitingTreatmentAntibody Mediated Rejection / End Stage Renal Disease (ESRD)1
4RecruitingTreatmentAutoimmune / Inflammatory Disorder1
4RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD) / Heart Failure, Unspecified1
4RecruitingTreatmentChronic Renal Failure (CRF) / Graft Failure / Kidney Transplant Rejection / Transplant; Failure, Kidney1
4RecruitingTreatmentChronic Rhinosinusitis Without Nasal Polyps1
4RecruitingTreatmentChronic Rhinosinusitis Without Nasal Polyps (CRSsNP)1
4RecruitingTreatmentCrohn's Disease (CD)1
4RecruitingTreatmentCrohn's Disease (CD) / Inflammatory Bowel Diseases (IBD)1
4RecruitingTreatmentGlomerulonephritis minimal lesion1
4RecruitingTreatmentHemophilia A With Inhibitors1
4RecruitingTreatmentImmunoglobulin G4 Related Sclerosing Disease1
4RecruitingTreatmentImmunosuppression1
4RecruitingTreatmentLupus Erythematosus / Lupus Erythematosus, Systemic / Tiredness1
4RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
4RecruitingTreatmentMantle Cell Lymphoma (MCL)1
4RecruitingTreatmentMetastatic Hormone Refractory Prostate Cancer1
4RecruitingTreatmentMultiple Myeloma (MM)1
4RecruitingTreatmentRecurrent Pregnancy Losses1
4RecruitingTreatmentTransplantation, Kidney1
4SuspendedTreatmentWegener's Granulomatosis or Microscopic Polyangiitis / Wegener's Granulomatosis, Microscopic Polyangiitis1
4TerminatedTreatmentAsthma Bronchial / Status Asthmaticus / Wheezing1
4TerminatedTreatmentDisseminated Sclerosis1
4TerminatedTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
4TerminatedTreatmentTransplantation, Kidney1
4TerminatedTreatmentTransplants and Implants1
4Unknown StatusNot AvailableKidney Diseases1
4Unknown StatusPreventionDiabetes Mellitus (DM) / Rejection, Transplant1
4Unknown StatusTreatmentAcute Lymphoblastic Leukaemias (ALL) / Non-Hodgkin's Lymphoma (NHL)1
4Unknown StatusTreatmentAsthma Bronchial1
4Unknown StatusTreatmentCrohn's Disease (CD)1
4Unknown StatusTreatmentEndocrine ophthalmopathy1
4Unknown StatusTreatmentGiant Cells Arteritis1
4Unknown StatusTreatmentGlomerular Diseases1
4Unknown StatusTreatmentInfections, Cytomegalovirus1
4Unknown StatusTreatmentPituitary Neoplasms / Postsurgical craniopharyngioma1
4WithdrawnNot AvailableProstate Neoplasms1
4WithdrawnTreatmentAcute Cellular Graft Rejection / Liver Transplant Rejection1
4WithdrawnTreatmentCardiac Sarcoidosis / Sarcoidosis1
4WithdrawnTreatmentCardiovascular Disease (CVD) / Cardiovascular Outcomes / Kidney Transplant Recipients / Transplantation, Kidney1
4WithdrawnTreatmentPneumonia, Pneumocystis Carinii1
Not AvailableActive Not RecruitingNot AvailableCrohn's Disease (CD) / Inflammatory Bowel Diseases (IBD)1
Not AvailableActive Not RecruitingTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableActive Not RecruitingTreatmentChildhood Lymphocyte Predominant Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma1
Not AvailableActive Not RecruitingTreatmentProstate Cancer1
Not AvailableCompletedNot AvailableDermatomyositis / Polymyositis1
Not AvailableCompletedNot AvailableInflammatory Bowel Diseases (IBD)1
Not AvailableCompletedNot AvailableLymphoma, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin's Lymphoma, Lymphoma, Non Hodgkin, Relapsed or Refractory Diffuse Large B-Cell Lymphoma1
Not AvailableCompletedNot AvailablePediatric Heart Transplant Recipients / Pediatric Heart Transplantation1
Not AvailableCompletedNot AvailableRheumatoid Arthritis2
Not AvailableCompletedDiagnosticAsthma Bronchial1
Not AvailableCompletedTreatmentAtaxia-Telangiectasia1
Not AvailableCompletedTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableCompletedTreatmentBell's Palsy1
Not AvailableCompletedTreatmentBlood and Marrow Transplant (BMT) / Graft Versus Host Disease (GVHD)1
Not AvailableCompletedTreatmentChronic Rhinosinusitis / Nasal Polyposis1
Not AvailableCompletedTreatmentEnd-Stage Renal Disease (ESRD)1
Not AvailableCompletedTreatmentHemangiomas1
Not AvailableCompletedTreatmentIgA Nephropathy1
Not AvailableCompletedTreatmentIgA Nephropathy (IgAN)1
Not AvailableCompletedTreatmentL1 Childhood Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia / Non-T, Non-B Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia1
Not AvailableCompletedTreatmentLeukemias2
Not AvailableCompletedTreatmentLeukopenia / Male Infertility / Oxidative Stress / Postinfection Inflammation1
Not AvailableCompletedTreatmentLymphoma, Large Cell / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableCompletedTreatmentLymphoma, Lymphoblastic1
Not AvailableCompletedTreatmentMalignant Lymphomas2
Not AvailableCompletedTreatmentPneumonia, Pneumocystis Jerovici1
Not AvailableCompletedTreatmentPost-Traumatic Stress Disorder (PTSD)1
Not AvailableCompletedTreatmentT-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableCompletedTreatmentTotal Hip Replacement1
Not AvailableNot Yet RecruitingNot AvailableGlucocorticoid therapy1
Not AvailableNot Yet RecruitingBasic ScienceAtopic Dermatitis (AD)1
Not AvailableNot Yet RecruitingTreatmentIdiopathic Membranous Nephropathy2
Not AvailableNot Yet RecruitingTreatmentPrimary IgA Nephropathy1
Not AvailableRecruitingNot AvailableAsthma Bronchial1
Not AvailableRecruitingNot AvailableBullous Pemphigoid (BP)1
Not AvailableRecruitingNot AvailableIgA Nephropathy / Immunosuppressive Treatment / Proteinuria in Nephrotic Range1
Not AvailableRecruitingHealth Services ResearchAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD)1
Not AvailableRecruitingOtherDelayed Type Hypersensitivity1
Not AvailableRecruitingTreatmentAdverse Effect of Glucocorticoids and Synthetic Analogues / Disease Exacerbation / Pulmonary Disease, Chronic Obstructive1
Not AvailableRecruitingTreatmentChronic Rhinosinusitis / Chronic Rhinosinusitis Without Polyps / Endoscopic Sinus Surgery / Oral Steroids1
Not AvailableRecruitingTreatmentClassical Hodgkins Lymphoma in Children and Adolescents1
Not AvailableRecruitingTreatmentDrug Reaction With Eosinophilia and Systemic Symptoms1
Not AvailableRecruitingTreatmentImmunosuppression1
Not AvailableRecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
Not AvailableRecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Non Hodgkin Lymphoma (NHL)1
Not AvailableRecruitingTreatmentNephrotic Syndrome,Idiopathic1
Not AvailableRecruitingTreatmentSystemic Lupus Erythematosus (SLE)1
Not AvailableRecruitingTreatmentTakayasu's Disease1
Not AvailableTerminatedNot AvailableBone destruction1
Not AvailableTerminatedTreatmentBruton's agammaglobulinemia / Chediak-Higashi Syndrome / Chronic Granulomatous Disease (CGD) / Common Variable Immunodeficiency / Familial Erythrophagocytic Lymphohistiocytosis / Graft Versus Host Disease (GVHD) / Immunologic Deficiency Syndromes / Leukocyte Adhesion Deficiency Syndrome / Lymphohistiocytosis, Hemophagocytic / Severe Combined Immunodeficiency / Virus-Associated Hemophagocytic Syndrome / Wiskott-Aldrich Syndrome (WAS) / X-Linked Hyper IgM Syndrome / X-Linked Lymphoproliferative Syndrome1
Not AvailableTerminatedTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
Not AvailableTerminatedTreatmentFollicular Lymphoma (FL) / Malignant Lymphomas / Marginal Zone Lymphoma1
Not AvailableTerminatedTreatmentPolycystic Liver Disease (PLD)1
Not AvailableTerminatedTreatmentProstate Cancer1
Not AvailableTerminatedTreatmentT-Cell Lymphomas1
Not AvailableUnknown StatusNot AvailableAsthma Exacerbations1
Not AvailableUnknown StatusNot AvailableExercise Performance in Copd Patients1
Not AvailableUnknown StatusSupportive CareCellulitis1
Not AvailableUnknown StatusTreatmentAnemia, Hemolytic, Autoimmune / Autoimmune Thrombocytopenic Purpura / Churg-Strauss Syndrome (CSS) / Giant Cells Arteritis / Graft Versus Host Disease (GVHD) / Granulomatosis With Polyangiitis / Polyarteritis Nodosa / Pure Red Cell Aplasia / Purpura, Schoenlein-Henoch / Rheumatoid Arthritis / Rheumatoid Arthritis, Juvenile / Systemic Lupus Erythematosus (SLE) / Takayasu's Disease / Vasculitis, Hypersensitivity1
Not AvailableUnknown StatusTreatmentDisseminated Sclerosis / Optic Neuritis1
Not AvailableUnknown StatusTreatmentGlomerulosclerosis, Focal Segmental1
Not AvailableUnknown StatusTreatmentIgA Glomerulonephritis1
Not AvailableUnknown StatusTreatmentLeukemias1
Not AvailableUnknown StatusTreatmentMalignant Lymphomas1
Not AvailableWithdrawnNot AvailableAcute Lymphoblastic Leukaemias (ALL) / Leukemias / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableWithdrawnDiagnosticMalignant Lymphomas1
Not AvailableWithdrawnTreatmentAsthma Bronchial1
Not AvailableWithdrawnTreatmentMalignant Lymphomas1

Pharmacoeconomics

Manufacturers
  • Schering corp sub schering plough corp
  • Roxane laboratories inc
  • Wockhardt eu operations (swiss) ag
  • Muro pharmaceutical inc
  • Halsey drug co inc
  • Bayer pharmaceuticals corp
  • Pharmacia and upjohn co
  • Ferndale laboratories inc
  • Solvay pharmaceuticals
  • Parke davis div warner lambert co
  • Schwarz pharma inc
  • American therapeutics inc
  • Amneal pharmaceuticals ny llc
  • Cm bundy co
  • Cadista pharmaceuticals inc
  • Contract pharmacal corp
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Elkins sinn div ah robins co inc
  • Everylife
  • John j ferrante
  • Heather drug co inc
  • Impax laboratories inc
  • Inwood laboratories inc sub forest laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kv pharmaceutical co
  • Lannett co inc
  • Lederle laboratories div american cyanamid co
  • Marshall pharmacal corp
  • Mutual pharmaceutical co inc
  • Nylos trading co inc
  • Panray corp sub ormont drug and chemical co inc
  • L perrigo co
  • Pharmavite pharmaceuticals
  • Phoenix laboratories inc
  • Purepac pharmaceutical co
  • Private formulations inc
  • Rexall drug co
  • Sandoz inc
  • Scherer laboratories inc
  • Sperti drug products inc
  • Superpharm corp
  • Teva pharmaceuticals usa inc
  • Udl laboratories inc
  • Upsher smith laboratories inc
  • Valeant pharmaceuticals international
  • Vangard laboratories inc div midway medical co
  • Vintage pharmaceuticals inc
  • Vitarine pharmaceuticals inc
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Whiteworth towne paulsen inc
Packagers
  • Advanced Pharmaceutical Services Inc.
  • Amend
  • Amerisource Health Services Corp.
  • Apotheca Inc.
  • Apothecary Shop Wholesale
  • AQ Pharmaceuticals Inc.
  • A-S Medication Solutions LLC
  • Breckenridge Pharmaceuticals
  • Bryant Ranch Prepack
  • C.O. Truxton Inc.
  • Cadista Pharmaceuticals Inc.
  • Cardinal Health
  • Carlisle Laboratories Inc.
  • Comprehensive Consultant Services Inc.
  • Corepharma LLC
  • Darby Dental Supply Co. Inc.
  • Dept Health Central Pharmacy
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Innoviant Pharmacy Inc.
  • Kaiser Foundation Hospital
  • Keltman Pharmaceuticals Inc.
  • Lake Erie Medical and Surgical Supply
  • Liberty Pharmaceuticals
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Merz Pharmaceuticals LLC
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mutual Pharmaceutical Co.
  • Neuman Distributors Inc.
  • Nucare Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Perrigo Co.
  • Pharmacia Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Prescription Dispensing Service Inc.
  • Qualitest
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Roxane Labs
  • Sandhills Packaging Inc.
  • Southwood Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • Stat Scripts LLC
  • Tya Pharmaceuticals
  • UDL Laboratories
  • Vangard Labs Inc.
  • Vedco Inc.
  • Veratex Corp.
  • Vintage Pharmaceuticals Inc.
  • Wa Butler Co.
  • Watson Pharmaceuticals
  • West-Ward Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral50 mg
TabletOral5 mg
Kit
TabletOral20 mg/20mg
TabletOral1.0 mg
TabletOral
SolutionOral5 mg/mL
TabletOral1 mg/1
TabletOral10 mg/201
TabletOral10 mg/1
TabletOral2.5 mg/1
TabletOral20 mg/201
TabletOral20 mg/1
TabletOral5 mg/1
TabletOral50 mg/1
Solution, concentrateOral5 mg/mL
Tablet, delayed releaseOral1 mg/1
Tablet, delayed releaseOral2 mg/1
Tablet, delayed releaseOral5 mg/1
TabletOral1 mg
Prices
Unit descriptionCostUnit
Sterapred DS 21 10 mg tablet Disp Pack64.0USD disp
Prednisone powder3.36USD g
Sterapred ds 10 mg tablet unipak2.93USD tablet
Prednisone 5 mg/ml solution1.17USD ml
PredniSONE 5 mg/5ml Solution0.5USD ml
Prednisone 50 mg tablet0.47USD tablet
Prednisone 20 mg tablet0.29USD tablet
Prednisone 10 mg tablet0.27USD tablet
Prednisone 2.5 mg tablet0.25USD tablet
Prednisone 1 mg tablet0.23USD tablet
Apo-Prednisone 50 mg Tablet0.18USD tablet
Winpred 1 mg Tablet0.12USD tablet
Apo-Prednisone 1 mg Tablet0.11USD tablet
Prednisone 5 mg tablet0.08USD tablet
Apo-Prednisone 5 mg Tablet0.04USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US9186332No2004-04-232024-04-23Us
US8168218No2008-01-072028-01-07Us
US8309124No2004-04-232024-04-23Us
US8394407No2004-04-232024-04-23Us
US9040085No2004-04-232024-04-23Us
US6488960No2000-03-142020-03-14Us
US6677326No2000-03-142020-03-14Us
US9504699No2007-08-032027-08-03Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)230 - 235 °C (decomposes)MSDS
water solubilityVery slightly solubleMSDS
logP1.46MSDS
Predicted Properties
PropertyValueSource
Water Solubility0.111 mg/mLALOGPS
logP2.07ALOGPS
logP1.66ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)12.58ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area91.67 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity97.57 m3·mol-1ChemAxon
Polarizability38.17 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9918
Blood Brain Barrier+0.9383
Caco-2 permeable-0.5096
P-glycoprotein substrateSubstrate0.7861
P-glycoprotein inhibitor INon-inhibitor0.7847
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.7463
CYP450 2C9 substrateNon-substrate0.8496
CYP450 2D6 substrateNon-substrate0.9138
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9406
CYP450 2C9 inhibitorNon-inhibitor0.9072
CYP450 2D6 inhibitorNon-inhibitor0.9418
CYP450 2C19 inhibitorNon-inhibitor0.9253
CYP450 3A4 inhibitorNon-inhibitor0.8902
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9095
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9597
BiodegradationNot ready biodegradable0.925
Rat acute toxicity1.8914 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.95
hERG inhibition (predictor II)Non-inhibitor0.584
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (12.5 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-05fs-2951000000-1a9b3a7e18f6088d28db
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-0900000000-1ea12664a8edc235b05c
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-1900000000-06d289c40615662ab14e
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-0900000000-f76738c3bedb48d0c7a3
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0019000000-d5b5ef89fce8ee6966ba
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00r5-0493000000-ae479d92cc77796a5177
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00ds-0690000000-f3df1438f8c0623811c1
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00dj-0970000000-b61d7f78a4036739cb07
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-05fs-0940000000-a9c08e5a06f9684fb000
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4l-0149000000-088a79de5c16e3384162
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-006w-2930000000-f901c87bc4fd3221d37e
MS/MS Spectrum - , positiveLC-MS/MSsplash10-05tg-0695000000-35841a4b47ea1535be95
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4m-0597000000-c12dc88504062b28c4be
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0002-2960000000-10bdddfba8bd2889acde

Taxonomy

Description
This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Hydroxysteroids
Direct Parent
21-hydroxysteroids
Alternative Parents
Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 3-oxo delta-1,4-steroids / 17-hydroxysteroids / 11-oxosteroids / Delta-1,4-steroids / Tertiary alcohols / Alpha-hydroxy ketones / Cyclic ketones / Cyclic alcohols and derivatives
show 3 more
Substituents
21-hydroxysteroid / Progestogin-skeleton / Pregnane-skeleton / 20-oxosteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 17-hydroxysteroid / Oxosteroid / 11-oxosteroid / Delta-1,4-steroid
show 13 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
17alpha-hydroxy steroid, glucocorticoid, 20-oxo steroid, 3-oxo-Delta(1),Delta(4)-steroid, 11-oxo steroid, 21-hydroxy steroid (CHEBI:8382) / Pregnane and derivatives [Fig] (C07370) / C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives (LMST02030180)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Liu BG, Li ZY, Du M: [Effects of jingui shenqi pill combined prednisone on expression of glucocorticoid receptor and its clinical effect in treating bullous pemphigoid patients]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006 Oct;26(10):881-4. [PubMed:17121036]
  2. Friel PN, Alexander T, Wright JV: Suppression of adrenal function by low-dose prednisone: assessment with 24-hour urinary steroid hormone profiles--a review of five cases. Altern Med Rev. 2006 Mar;11(1):40-6. [PubMed:16597193]
  3. Diez JJ, Iglesias P: Pharmacological therapy of Cushing's syndrome: drugs and indications. Mini Rev Med Chem. 2007 May;7(5):467-80. [PubMed:17504182]
  4. Yano A, Fujii Y, Iwai A, Kawakami S, Kageyama Y, Kihara K: Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6012-7. [PubMed:17062674]
  5. Yano A, Fujii Y, Iwai A, Kageyama Y, Kihara K: Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res. 2006 May 15;12(10):3003-9. [PubMed:16707595]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Ligand
General Function
11-beta-hydroxysteroid dehydrogenase [nad(p)] activity
Specific Function
Catalyzes reversibly the conversion of cortisol to the inactive metabolite cortisone. Catalyzes reversibly the conversion of 7-ketocholesterol to 7-beta-hydroxycholesterol. In intact cells, the rea...
Gene Name
HSD11B1
Uniprot ID
P28845
Uniprot Name
Corticosteroid 11-beta-dehydrogenase isozyme 1
Molecular Weight
32400.665 Da
References
  1. Raza K, Hardy R, Cooper MS: The 11beta-hydroxysteroid dehydrogenase enzymes--arbiters of the effects of glucocorticoids in synovium and bone. Rheumatology (Oxford). 2010 Nov;49(11):2016-23. doi: 10.1093/rheumatology/keq212. Epub 2010 Jul 15. [PubMed:20634231]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Ferry JJ, Wagner JG: The nonlinear pharmacokinetics of prednisone and prednisolone. II. Plasma protein binding of prednisone and prednisolone in rabbit and human plasma. Biopharm Drug Dispos. 1987 May-Jun;8(3):261-72. [PubMed:3593903]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103]
  2. Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. [PubMed:14661924]
  3. Dilger K, Schwab M, Fromm MF: Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein. Inflamm Bowel Dis. 2004 Sep;10(5):578-83. [PubMed:15472518]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. [PubMed:8786566]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:42